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Cancer is a disease in which cells acquire the ability to divide uncontrollably and invade other 
tissues. An important component of this process is the activation of oncogenes and 
inactivation of tumor suppressor genes. The MYC family of oncogenes, consisting of MYC, 
MYCN and MYCL, is frequently deregulated in human cancer, and is often associated with 
aggressive disease, resistance to treatment and poor outcome. MYC encodes a transcription 
factor that controls many essential cellular processes of relevance for tumor development. In 
this thesis, two such MYC-regulated processes have been in focus: cellular senescence and 
immune modulation. Previous work has shown that MYC suppresses cellular senescence, 
which together with apoptosis is an important barrier against tumor development. Recent 
studies have also shown an important role for MYC in escape from immune surveillance.  
Due to the central role of MYC in cancer there is an increasing interest in targeting MYC, 
which for a long time have been considered “undruggable”. However, to function as a 
transcription factor, MYC needs to interact with several partner proteins. Two such proteins 
in the focus of this thesis are MAX and cyclin-dependent kinase 2 (CDK2). Targeting these 
interactions or the activities of partner proteins are plausible ways of inhibiting MYC 
function. This thesis centres around evaluating these two different strategies to inhibit MYC 
functions and develop new treatments for cancer therapy. We reported previously that 
suppression of senescence by MYC requires CDK2-mediated phosphorylation of MYC at 
serine 62, and that ablation of CDK2 activity results in senescence induction in vitro. In the 
first part of this thesis, encompassing paper I and II, we evaluated the role of CDK2 for MYC-
mediated suppression of senescence and for MYC-driven tumor development in vivo using 
depletion and pharmacological inhibition of CDK2 in two MYC-driven mouse tumor models 
representing acute myeloblastic leukemia (AML) and lung tumors. 
 
In paper I, we utilised a mouse AML model driven by MYC and the anti-apoptotic factor 
BCL-XL, Hematopoietic stem cells (HSC) purified from bone marrow cells of mice were 
transduced with lentiviral vectors containing MYC and BCL-XL and then transplanted into 
lethally irradiated mice. Untreated mice developed massive AML-like leukemia after 2-3 
weeks of transplantation. The mice were treated with the CDK2 inhibitor CVT2584 or 
vehicle upon disease onset, either by daily intraperitoneal injections or through continuous 
delivery via mini-pumps. Analysis of isolated bone marrow, liver and spleen cells of mice by 
flow cytometry revealed a significant decrease of the leukemic AML cell population in the 
treated mice. CDK2 targeting reduced phosphorylation of MYC at Ser 62 in leukemic cells, 
significantly delayed onset of disease and improved mice survival. This was associated with 
induction of senescence, as measured by the decrease in proliferation, increase in senescence 
associated β-gal activity, H3K9me3 heterochromatin foci, p19ARF and p21CIP1, and activation 
of pRb.  
 
In paper II, we utilized a conditional immunocompetent mouse lung tumor model induced by 
CRE-mediated recombination of mutant BRAFV600E and the MycER fusion protein through 
inhalation of Ad-CRE virus. In addition, MYC activity in this system is regulated by 
tamoxifen. These mice were cross-bred with conditional CDK2 knockout mice, to create a 
model where CDK2 is deleted by Ad-CRE simultaneously with activation of the two other 
loci. Depletion of CDK2 resulted in delayed/inhibited tumor development and significant 
enhancement of overall survival. This was associated with induction of senescence in tumors 
lacking CDK2, evidenced by reduced tumor cell proliferation and pRB phosphorylation, and 
induction of p21CIP1 and H3K9me3. Similar results were obtained by pharmacological 
inhibition of CDK2. RNA-Seq analysis of whole lung tissue revealed that CDK2 loss 
counteracted MYC activity and induced the expression of genes representing the senescence-
associated secretory phenotype (SASP) and genes involved in immune cell recruitment and 
 
 
activation. Supporting this notion, immunofluorescence staining demonstrated an increase 
infiltration of T-, and B-cells and macrophages in the lungs of CDK2-deficient mice 
irrespective of MycER status. Further, FACS analysis of immune cell populations in the lung 
revealed a significant increase in CD8+ T cells, macrophages and activated NK cells, and a 
reduction in CD4+ T cells, in response to CDK2 depletion. Finally, examination of the effect 
of MYC deactivation in CDK2-depleted tumors showed a massive reduction in tumor burden.  
Collectively, our results demonstrate that inhibition/depletion of CDK2 inhibited AML and 
lung tumor development linked to induction of cellular senescence. Additionally, we uncover 
a promising potential role for CDK2 in modulating immune surveillance. 
 
MAX is a dimerization partner that is essential for MYC’s function as a transcription factor, 
and this interaction is therefore a promising target to abrogate MYC activity in cancer cells. 
In the second part of the thesis, covering paper III and IV, we identified and characterized 
small molecules inhibiting MYC:MAX interaction. Using a cell-based MYC:MAX 
interaction inhibitor screen employing bimolecular fluorescence complementation (BiFC) 
assay, we identified six compounds, named MYC:MAX inhibitors (MYCMIs), specifically 
reducing the BiFC signal. The effect of the compounds on MYC:MAX interaction was 
further validated in cells utilizing split Gaussia luciferase (GLuc), in situ proximity ligation 
assay (isPLA), co-immunoprecipitation as well as functional studies using chromatin 
immunoprecipitation and analysis of MYC target gene expression. This showed that 
MYCMI-6 and MYCMI-7 were the most potent and selective MYC:MAX inhibitors with 
IC50s in the single digit micromolar range. Next, we examined direct binding of MYCMI-6 
and MYCMI-7 to recombinant bHLHZip domains of MYC and MAX in vitro, using 
microscale thermophoresis (MST) and surface plasmon resonance (SPR) assays. The results 
showed that MYCMI-6 and MYCMI-7 both bound directly and selectively to MYC with a 
KD of 1.6 and 4.3 µM, respectively, but did not bind MAX to any greater extent. Analysis of 
MYC expression showed that MYCMI-7 reduced MYC protein levels while MYCMI-6 did 
not. Evaluation of the inhibitory effects of MYCMI-6 and MYCMI-7 on MYC-dependent 
cell growth showed that MYC-expressing transformed cells were highly sensitive, while 
MYC-null cells were largely unaffected.   Further, MYCMI-6 and MYCMI-7 strongly 
reduced growth/viability of different MYC-driven cancer cell lines, including MYCN-
amplified neuroblastoma and Burkitt’s lymphoma cells at single digit µM concentrations, 
and significant correlation between MYC mRNA/protein levels and the sensitivity to 
treatment was observed in the NCI-60 human tumor cell line panel. Importantly, both 
compounds caused growth arrest but did not have cytotoxic effects on normal cells. Finally, 
treatment with MYCMI-6 and MYCMI-7 in vivo using an MYCN-amplified neuroblastoma 
xenograft mouse model resulted in reduced MYCN activity/expression, reduced tumor 
burden and massive apoptosis and necrosis in the tumor tissue, without causing severe side 
effects. Further experiments using MYCMI-7 treatment showed similar effects in mouse 
tumor models of AML and breast cancer, resulting in increased survival in the neuroblastoma 
and breast cancer models. The results obtained from MYCMI-6 and MYCMI-7 are 
encouraging and warrant further investigation with respect to their mechanism of action and 
the improvement of their efficacy and bioactivity for further pre-clinical/clinical 
development.  
  
In conclusion, the two approaches to interfere with MYC function presented in this thesis -  
inhibition of CDK2 and of MYC:MAX interaction - showed promising results and can 
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1.1 Cancer Biology 
 
Cancer, which is another term used to describe malignant tumors, is one of the leading 
causes of death around the world, with over than 1.8 million new cases and over 600,000 
deaths in the USA alone during 2019 (Siegel, Miller, & Jemal, 2020). It’s a disease which 
arises when cells gain uncontrollable capacity to divide and eventually invade other 
organs within the body, resulting in organ failure and ultimately leading to death. Cancer 
is a result of genetic mutations and epigenetic changes which occur due to errors in DNA 
replication and/or DNA damage by environmental factors during our lifetime. These 
factors include exposure to radiation, such as UV-radiation, and chemical compounds that 
can cause genetic mutations, termed carcinogens, found in tobacco smoke, for example 
(Borek, 1993)(World Health Organization, 2018). Other environmental factors include 
among others, physical agents, such as cobalt or other heavy metals, dietary factors, like 
aflatoxin B1 and biological agents, for instance, human papilloma virus and Kaposi 
sarcoma virus (Bast, 2000; Ljubojevic & Skerlev, 2014; Park, Bae, Nam, & Yoo, 2008; 
Weiss & Boshoff, 2000). Mutations accumulated due to exposure to these agents over a 
life span may lead to cancer development. A subset of cancers, 5-10%, arise from genetic 
mutation in the germline that are inherited, thus called hereditary cancers (National 
Cancer Institute, 2015). Individuals with these germline mutations are predisposed to 
cancer development, which often manifest early on in life. During both the hereditary and 
non-hereditary cancer development process, the genetic mutations acquired by the cancer 
cells render them irresponsive to normal cell regulation mechanisms and allow them to 
gain certain capabilities that boost their growth and survivability. These include many 
capabilities, or hallmarks, which were originally proposed and expanded on by Robert 
Weinberg and Douglas Hanahan. For instance, tumor cells gain the ability to proliferate 
without the need for external growth signals (self-sustained proliferative signalling) and 
acquire resistance to external antigrowth signals (irresponsiveness to antigrowth signals). 
They also have the ability to divide indefinitely (immortality), cell death escape, stimulate 
the growth of new blood vessels (angiogenesis), evade recognition and destruction by the 
immune system and can invade distant tissues (metastasis) (Hanahan & Weinberg, 2011).  
 
Over the last 50 years or so, different types of therapies to combat cancer have been 
developed, some of which have been quite successful, but most advanced, metastatic 
cancers are still incurable. Traditional cancer therapies primarily consist of chemotherapy, 
radiotherapy and surgical removal. In chemotherapy, the patients are given one or several 
chemotherapeutic agents that kill dividing cells. These agents are not specific and also 
affect normal cells, which results in many side effects. Additionally, resistance to these 
chemotherapeutic agents is often observed in cancer cells, giving rise to more aggressive 
tumors (Fernando & Jones, 2015). The other line of cancer treatment consists of the use 
directed ionizing irradiation to kill cancer cells, often in combination with chemotherapy 
or after surgical removal of the tumor mass. Despite its localized toxic effect, due to its 
nature, radiotherapy can cause new mutations in normal cells and the subsequent 




therapy approach includes surgery, in which the tumor mass is surgically removed. While 
less toxic than chemotherapy and radiotherapy, the size and location of the tumor, such 
as vicinity to vital organs, set limitations for this procedure. In addition, if metastatic 
spread of the tumor has occurred, surgery will not be effective. These issues highlight the 
need for less toxic and more effective therapies to improve the outcome for cancer 
patients. During the past decade, the better understanding of cancer biology led to a surge 
in the development of new promising cancer therapies, such as targeted therapy and 
immunotherapy, opening the way to achieve better and more robust cancer therapies. 
Following this brief introduction on cancer, I will proceed to go more in details on 
different aspects in cancer and tumor biology, as well as a potential new therapy, that are 
the focus of this thesis.  
 
1.1.1   Cell signal transduction 
 
To better understand some of the mechanisms involved in the process of carcinogenesis 
that I will discuss later in this introduction, it is vital to understand the process of cellular 
signal transduction. Signal transduction is the mechanism in which cells respond to 
external stimuli from surrounding environment and transmit the signal into the cell 
interior through a cascade of events and convert it into functional cellular activities. It is 
through this mechanism that cells initiate cellular processes such as proliferation, growth 
and cell migration. This process is dependent on small molecules that cells produce called 
ligands, which for instance can be growth factors, hormones or cytokines. These ligands, 
once secreted outside of the cell, can recognize and bind specifically to cell surface 
proteins known as receptors. Once a ligand binds its receptor, it will activate an internal 
signalling cascade and trigger different processes within the cell. There are many different 
receptors expressed on the surface of different cells, such as receptor tyrosine kinases 
(RTK), Frizzled family receptors, NOTCH receptors, nuclear receptors etc., all of which 
regulate cellular pathways and processes that are deregulated in cancer cells.  
 
One of the most important cells signalling pathways that are commonly involved in 
different cancers, as well as of relevance to this thesis work, is the RAS pathway. The 
RAS protein belongs to the small GTPase involved in mitogen-activated signalling 
transduction in mammalian cells. This pathway is activated in response to many 
mitogenic signalling molecules such as epidermal growth factor (EGF), platelet-derived 
growth factor (PDGF) and insulin-like growth factor (IGF) through cell membrane 
receptors such as receptor tyrosine kinases; in these cases, the EGF receptor (EGFR), 
PDGF receptor (PDGFR) and IGF receptor (IGFR), respectively. RAS is activated 
following its binding of GTP, facilitated by guanine nucleotide exchange factors (GEFs). 
RAS has an intrinsic GTPase activity, which hydrolyse the bound GTP and convert it to 
GDP, resulting in RAS inactivation. The RAS GTPase activity is stabilized and enhanced 
by the GTPase-activating proteins (GAPs) for efficient deactivation (Vetter et. Al, 2001). 
Following its activation, RAS recruits, binds and activates several downstream effector 
proteins involved in different cellular mechanisms. One example of these effector 
proteins is RAF, found in 3 different homologous forms (BRAF, c-RAF-1 and ARAF). 
Once bound by RAS, the activated RAF triggers the Mitogen-Activated Protein Kinase 
(MAPK)/ERK pathway. Activated RAF starts a phosphorylation and activation cascade 
in which it interacts with and phosphorylate mitogen-activated protein kinases (MEKs) 1 
 
 3 
and 2, resulting in their activation. MEK1/2 in turn phosphorylates and activates 
extracellular signal-regulated kinases (ERKs) 1 and 2. In turn, ERK1/2 proceeds to 
phosphorylate and activate a variety of cellular proteins, including transcription factors. 
One of the ERK1/2 targets is ELK1, a transcription factor from the ETS family 
transcription factors, which induces the expression of another transcription factor named 
FOS. Additionally, ERK1/2 phosphorylates the transcription factor JUN. Together, FOS 
and JUN form the heterodimer AP-1, a transcription factor complex involved in 
expression of genes required for cell cycle progression, such as cyclin D1 (also known as 
CCND1) (Albanese et. al, 1995)(Karin et. al, 1997). Furthermore, ERK promotes tRNA 
and 5S rRNA synthesis by phosphorylating B-related Factor 1 (BRF1), part of the RNA 
polymerase (pol) III-specific transcription factor (TFIIIB) complex (Felton-Edkins et. al, 
2003). 
 
Another major pathway induced by RAS activation is the phosphatidylinositol 3-kinase 
(PI3K) pathway. Upon activation, RAS binds PI3K through the RAS-binding domain 
(RBD) on the PI3K p110 catalytic subunit and leads to PI3K activation (Rodriguez-
Viciana et. al, 1994). PI3K is a kinase that can phosphorylate membrane 
phosphatidylinositol. The PI3K protein is found as heterodimers in cells and consists of 
2 subunits: a regulatory subunit (p85) and catalytic subunits (p110 α, β, γ, and δ)(Geering 
B. et. al, 2007). PI3K binding to RAS activates the PI3K catalytic subunit (p110), 
resulting in phosphorylation of the membrane-bound phosphatidylinositol-4,5-
bisphosphate (PIP2) to produce phosphatidylinositol-3,4,5-trisphosphate (PIP3) (Zhao L. 
et. al, 2008). The production of PIP3 results in the recruitment of AKT (also known as 
Protein Kinase B (PKB)), which binds preferentially to PIP3 via its plekstrin homology 
(PH) domain. Upon its binding to PIP3, AKT/PKB undergoes conformational change, 
allowing it to bind 3'-phosphoinositide-dependent kinase-1 (PDK1) (Barry and Gibbins, 
2002). Following their interaction, PDK1 phosphorylates and activates AKT/PKB (Wick 
et. al, 2000). AKT/PKB is involved in many cellular processes. For instance, AKT/PKB 
has been shown to phosphorylate and inhibit Glycogen Synthase Kinase-3β (GSK3β) 
(Cross et. al, 1995). GSK3β is a serine-threonine kinase that is involved in β-catenin 
regulation, by promoting β-catenin degradation mediated by β-TRCP and the APC- Axin 
E3 ligase complex (Orford et. al, 1997). GSK3β inhibition by AKT/PKB allows β-catenin 
to escape GSK3β-mediated degradation and translocate to the nucleus, where it activates 
the expression of genes involved in proliferation, such as cyclin D1 (CCND1) and MYC. 
Furthermore, AKT/PKB phosphorylation of GSK3β prevents the phosphorylation of 
MYC by GSK3β, contributing to MYC protein stability and resulting in stronger overall 
proliferative signal. Activated AKT/PKB phosphorylates cell cycle regulators p21CIP1 and 
p27KIP1, leading to their re-localization to the cytoplasm and freeing the CDK2-Cyclin E1 
complex and promoting S phase entry (Liang et. al, 2002)(Zhou et. al, 2001). Increased 
protein synthesis is also required for cells in order to undergo growth and proliferation. 
This is regulated by the mTOR serine/threonine kinase, which consists of two core 
subunits: mammalian target of rapamycin complex 1 and complex 2 (mTORC1 and 
mTORC2, respectively). the mTOR pathway is involved in the regulation of many 
cellular processes, including cell growth, proliferation and survival, cell motility, cell 
survival, protein synthesis, autophagy, and transcription (Hay & Sonenberg, 2004). 
AKT/PKB stimulates translation through phosphorylation of mTORC2 on the serine 473 




1 (mTORC1) activation by blocking Tuberous Sclerosis Complex 2 (TSC2), thereby 
promoting protein synthesis required for cell growth (Muise-Helmericks et. al, 1998)(Gao 
et. al, 2004). The role of the PI3K-AKT/PKB pathway extends to regulating cell survival 
and apoptosis, as we will see in the section below.  
 
1.1.2 Oncogenes and Tumor Suppressor Genes 
 
Early research in the cancer field have identified certain genes that are involved in the 
process of tumor development. The functions or the regulation of these genes are often 
altered through different mechanisms and these alterations usually provide survival and 
growth advantages required for cancer cells development and maintenance. These genes 
are divided into two main groups based on their contributions to cancer development, 
termed oncogenes and tumor suppressor genes.  
Oncogenes are genes driving tumorigenesis. They are usually involved in cell 
proliferation, growth and/or survival and become deregulated as a result of oncogenic 
events. Under normal physiological conditions, oncogenes are tightly controlled within the 
cell and are referred to as proto-oncogenes. During cancer development, these genes are 
deregulated, by mutations for instance, thus becoming oncogenes. They usually encode 
proteins that drive cell proliferation, growth and survival. While the theory of oncogenes 
was proposed since the early 1900s, the first oncogene to be confirmed was in 1970 by G. 
Steven Martin, based on Francis Peyton Rous work on v-SRC from Rous sarcoma virus 
(RSV) in 1911(Martin, 2001; Rous, 1911). This was shortly followed by the discovery of 
v-SRC homolog in humans by Michael bishop and Harold Varmus, which they named c-
SRC (Stehelin, Varmus, Bishop, & Vogt, 1976). Following those discoveries, numerous 
oncogenes such as RAS, MYC and ERBB2 were identified and characterized. Oncogenes 
are deregulated in different ways; they can be overexpressed through gene duplication or 
acquire mutations that render them constitutively active and irresponsive to inhibitory 
cellular signals. An example of an oncogene that is a result of genetic mutations is RAS. 
RAS is frequently deregulated in tumor cells through missense mutations affecting its 
ability to exchange GTP for GDP, resulting in constitutively active RAS signalling. 
Additionally, similar genetic alterations also involved in the deregulation and activation of 
RAS downstream effectors, such as BRAF (Bos et. al, 1989)(Pratilas & Solit, 2010). 
Another mechanism in which they are deregulated is through translocations. Some 
translocations can result in gene fusions, where the product results in an oncogenic protein. 
A classic example of such translocations is BCR-ABL1 fusion gene resulting from a 
reciprocal translocation between q34 on chromosome 9, containing the Tyrosine-protein 
kinase (ABL) and part of the BCR (breakpoint cluster region) gene on chromosome 22, 
which gives rise to different types of leukaemia (Kurzrock, Kantarjian, Druker, & Talpaz, 
2003; Pakakasama et al., 2008). These alterations provide cancer cells with a continuous 
proliferation signal and the blockage of apoptosis by RAS downstream effectors through 
the PI3K pathway. Additionally, some translocations place them under highly active 
promoters, for instance, and drive their high expression. An example of this is MYC, a 
transcription factor involved in the regulation a wide variety of cellular processes, and 
which will be discussed in more detail further below. Taken together, deregulation of 
oncogenes is a key event needed for tumor development.  
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The other set of important genes in the process of carcinogenesis are tumor suppressor 
genes, such as p53, retinoblastoma gene (RB), phosphatase and tensin homolog (PTEN) 
and cyclin-dependent kinase inhibitor 2A (CDKN2A) (also known as p16INK4a). These 
genes give rise to proteins involved in cell cycle regulation, induction of apoptosis and/or 
DNA repair mechanisms. They act as ¨guardians¨ to prevent cells with abnormalities from 
becoming cancerous cells as they block and counter the effects of oncogenes. During the 
process of carcinogenesis, tumor suppressor genes are either inactivated or lose their 
function, an integral step towards cancer transformation. This is achieved through missense 
point mutations that result in a loss of function, genetic deletions of the tumor suppressor 
gene or via epigenetic silencing by hypermethylation of tumor suppressor gene loci, which 
block their expression. For example, tumor suppressor protein p53 is mutated in more than 
50% of human cancers (Surget, Khoury, & Bourdon, 2013). This transcription factor plays 
an important role in regulating many cellular processes crucial for cell survival and 
tumorigenesis, in which it acts to protect cells from oncogenic transformation. p53 is 
involved in the activation of programmed-cell death (also known as apoptosis) and 
permanent growth arrest (also known as senescence), two important barriers against 
tumorigenesis, in response to oncogenic signals and DNA damage, which I will discuss 
later in this introduction. Its role in blocking tumor transformation is widely demonstrated 
in numerous cancer studies. For instance, it has been shown to inhibit MYC and RAS 
(Buganim et al., 2010; Ho, Ma, Mao, & Benchimol, 2005). Other processes inhibited by 
p53 is angiogenesis. Angiogenesis is controlled by the transcription factor hypoxia-
inducible factor 1-alpha (HIF-1α, which regulates many genes involved in this process, 
including vascular endothelial growth factor-A (VEGF-A). It has been reported that p53 
induces HIF-1α degradation, leading to the reduced release of VEGF-A) (Sermeus & 
Michiels, 2011). p53 often undergoes loss of function in cancer cells due to missense 
mutations in the DNA-binding domain, crippling its ability to activate genes (Levine & 
Lane, 2010). In addition to direct inhibition of p53 by genetic deletions and mutations, 
cancer cells also upregulate Mouse double minute 2 homolog (MDM2), a negative 
regulator that binds p53, blocks its transcriptional activity and induces p53 degradation 
(Fuchs, Adler, Buschmann, Wu, & Ronai, 1998; Moll & Petrenko, 2003).  pRB is also 
found to be inactivated in many human cancers. pRB regulates the progression from G1 of 
the cell cycle into the S phase of the cell cycle by binding transcription factor E2F, an 
activator of crucial positive cell cycle regulators, preventing target gene expression. 
Mutated pRB loses its ability to bind E2F, resulting in S phase entry (Burkhart & Sage, 
2008). Other tumor suppressor genes that are inactivated in cancer includes PTEN by 
genetic deletion, and CDKN2A, through hypermethylation of its promoter. PTEN is a 
phosphatase involved in the dephosphorylation of phosphoinositide substrates such as 
PIP3, thereby blocking the AKT/PKB pathway, while CDKN2A is a negative regulator of 
the cycle, which I will discuss in the following section (Cantley & Neel, 1999). The 
inactivation of oncogenes and the de-activation of tumor suppressor genes are thus crucial 
in the process of carcinogenesis, as such, we well explore their roles in some of these 
processes within the different sections of this introduction.  
 
1.1.3   The cell cycle 
 
During the life span if a cell, it goes through a fundamental process called the cell cycle, in 




many different proteins to insure a proper and viable cell division. The cell cycle can be 
divided into four phases: the DNA synthesis (S) phase, the mitosis and cell division (M) 
phase, and two growth phases in between called gap1 (G1) and gap 2 (G2). The cell cycle 
starts with the G1 phase, where the cell accumulates mRNA and proteins needed for the S 
phase. Once in the S phase, the cell duplicates its DNA content. In the next phase, G2, cells 
continue to synthesize cellular proteins and ensuring successful DNA replication. 
Following G2, the cell enters the mitotic phase. Mitosis is the process in which the 
replicated chromosomes and contents of the cytoplasm, duplicated during the previous 
phases of the cell cycle, separate, after which the cell divides into two identical daughter 
cells. It consists of several stages; prophase, prometaphase, metaphase, anaphase,  telophase 
and culminating in cytokinesis to produce two daughter cells. Once completed, the cell 
either re-enter into G1 or go into a quiescent state called G0, in which cells stop dividing 
either temporarily or permanently. 
 
As mentioned above, this process involves interplay between a variety of cellular proteins 
through the different phases. The main group of proteins driving the cell cycle progression 
are called cyclins and cyclin-dependent kinases (CDKs). Cyclins belong to a family of 
proteins consisting of cyclin D, E, A and B, that exhibit a varying expression pattern 
through the cell cycle (see below). They form complexes with CDKs during different stages 
in the cell cycle, a step required for the activation of CDKs and their binding to the 
substrates. Unlike cyclins, CDKs expression level is mostly stable through the cell cycle. 
While cyclins lack enzymatic activity, CDKs are a group of serine/threonine protein kinases 
that, once activated, act on different substrates required for cell cycle progression (Morgan, 
2006). This group of proteins consist of many members, with CDK1, 2, 4 and 6 being the 
most crucial for cell cycle progression. Once the cell receives growth signal via its ligand-
activated growth receptors, such as EGF, the consequent signal transduction results in the 
activation of cyclin D expression (Albanese et al., 1995). Cyclin D forms a complex with 
CDK4 or CDK6, which is detected by CDK-activating kinase (CAK) that phosphorylates 
and activates the cyclin D-CDK4/6 complex (Morgan, 2006). Once activated, cyclin D-
CDK4/6 drive the cell through a mandatory check point in G1 phase, known as the R point, 
by phosphorylating E2F-bound pRB. The phosphorylation of pRB by cyclin D-CDK4/6 is 
followed by the hyperphosphorylation of pRB by the cyclin E-CDK2 complex. In its 
hyperphosphorylated form, pRB is inactivated and dissociates from E2F, allowing E2F to 
induce the expression of genes required for S phase entry (Giacinti & Giordano, 2006). 
During early S phase, cyclin E is replaced by cyclin A, an E2F target gene, as CDK2 partner 
and promote DNA synthesis initiation. Towards the end of the S phase, cyclin A-CDK2 
complexs are degraded and replaced by cyclin A-CDK1 compleses that facilitates entry to 
the G2 phase of the cell cycle (Weinberg, 2007). During the G2 phase, when the 
chromosomes exit in a duplicated form, the DNA repair machinery can utilize homologous 
recombination to repair persisting DNA damage occurring in S phase as well as the 
continuation of protein synthesis in preparation for the mitosis phase. At the late G2 phase, 
the cell passes through the G2/M checkpoint to ensure that the DNA is repaired and ready 
for mitosis (Burgoyne, Mahadevaiah, & Turner, 2007). Shortly following M phase entry, 
cyclin A is replaced by cyclin B to form cyclin B-CDK1 complexs, which are activated by 
CDC25 phosphatase to guide the cell through mitosis. At the final stage of mitosis, cyclin 
B is degraded by Anaphase-Promoting Complex (APC) and the daughter cells exit the M 
phase by cytokinesis and proceed to G1 or reside in G0. 
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Aside from the cyclins and CDKs, another group of proteins are also actively involved in 
the regulation of this process. This group proteins consist of cyclin-dependent kinase 
inhibitors (CDKIs) belonging to two families, the INK4a family and the CIP/KIP family. 
The INK4a gene family includes CDKN2A (p16), CDKN2B (p15), CDKN2C (p18) and 
CDKN2D (p19) which mainly inhibits the cyclin D-CDK4 complex.  The CIP/KIP gene 
family includes CDKN1A (p21CIP1), CDKN1B (p27KIP1) and CDKN1C (p57) and act on 
the CDK1 and CDK2 complexes (Weinberg, 2007). These proteins negatively regulate cell 
cycle progression and prevent cells from proliferating uncontrollably and are induced in 
response to stress signals, such as DNA damage, replication stress and aberrant oncogenic 
activation. For instance, oncogenic activation of RAS induces replication stress signals that 
activates p16 (Rayess, Wang, & Srivatsan, 2012). In turn, p16 proceeds to block cyclin D-
CDK4/6 activity by binding CDK4 and preventing its association with cyclin D, blocking 
E2F release from pRB and halting cell cycle progression (Parry, Bates, Mann, & Peters, 
1995; Serrano, Hannon, & Beach, 1993). In the case of DNA damage, DNA damage 
response (DDR) activates p53, which proceed to induce p21CIP1 expression. p21CIP1 acts by 
binding CDK2 and CDK1, which block their ability to form complexes with their respective 
cyclins and advancing the cell cycle (Harper et al., 1995). In similar fashion, other CDKIs 
bind and block the function of different CDKs to keep malfunctioning cells from 
proliferating and causing diseases such as cancer. Due to their strong negative effect on cell 
cycle progression, CDKIs are often inactivated in cancer cells.  For instance, p16 and 
p21CIP1 have been shown to be inactivated in cancer cells through repressive 
hypermethylation marks in their promoters (Gartel et al., 2001). Additionally, positive 
Figure 1: General schematic view of the regulation of the mammalian cell cycle. Adopted from Petroni 
G, Formenti SC, Chen-Kiang S, Galluzzi L.et al., Immunomodulation by anticancer cell cycle inhibitors. 




regulators of cell cycle progression are also deregulated in cancer. Cyclin E has been 
found to be deregulated and overexpressed by different mechanism in a variety of human 
cancers, including breast cancer and colon cancer (Donnellan & Chetty, 1999; Yasui et 
al., 1996). These observations highlight the importance of the cell cycle regulators and 
their fundamental role in cancer development.  
 
1.1.4   Apoptosis 
 
Over our life span, cells within different tissues get exposed to many harmful physical, 
chemical and biological agents. These agents cause tissue damage and can lead to 
dysfunctional cells capable of developing tumors. To prevent this, cells have acquired 
different fail-safe mechanism that are programmed to trigger cell cycle arrest or cell death 
in dysfunctional cells. One of these cellular mechanisms is apoptosis. Apoptosis is a 
process of controlled and programmed cell death, that results in clearance of 
malfunctioning cells, without causing trauma or damage to the surrounding cells within 
the tissue. This mechanism is triggered in response to stress signals, such DNA damage, 
oncogene-induced replication stress and viral infection. There are two main pathways to 
activate the apoptotic machinery; the intrinsic pathway and the extrinsic pathway (Koff, 
Ramachandiran, & Bernal-Mizrachi, 2015). Each of the pathways is driven by a group of 
proteolytic proteins called caspases. The caspases are divided into 2 groups, based on 
their function; initiator caspases, which includes caspase 2, 8, 9 and 10, and executioner 
caspases, which includes caspases 3, 6 and 7. As their naming suggests, initiator caspases 
facilitate the apoptotic cascade while the executioner caspases cleave and degrade the 
different cellular components during apoptosis. The activation of one, or both, of these 
pathways ultimately results in cell death. 
 
The intrinsic pathway is triggered for instance in response to DNA damage that cells are 
unable to repair, for example due to replication stress or exposure to UV irradiation 
(Bernstein, Bernstein, Payne, & Garewal, 2002). Unlike the external pathway, this 
pathway does not require external cellular signals. Unresolved DNA damage triggers 
DDR response signalling that induces p53, which proceeds to activate the expression of 
several pro-apoptotic factors including BAX, BIM and NOXA. These proteins in turn 
translocate to the mitochondria, where they bind to anti-apoptotic factors bound to outer 
membrane, such as BCL-2 and BCL-XL, causing cytochrome c release (Gross, Jockel, 
Wei, & Korsmeyer, 1998). Once released, cytochrome c binds to the Apoptotic Protease 
Activating Factor (APAF) and proceeds to cleave and activate caspase 9 (P. Li et al., 
1997; Weng, Li, Xu, Shi, & Tang, 2005). Activated caspase 9 then form a complex with 
cytochrome c and APAF called the apoptosome, which cleave and activate the 
executioner caspases, resulting in the degradation of the different cellular components 
and cell death. 
 
While the intrinsic pathway is a consequence of signals from within the cell, the extrinsic 
pathway is triggered by signal from the surrounding microenvironment. In this pathway, 
death receptors of the Tumor Necrosis Factor (TNF) superfamily, such as TNF-alpha 
receptor and FAS, are activated by TNF-alpha (TNF-α) or FAS ligand (FasL), secreted 
by immune cells for instance (Wajant, 2002). The intracellular domain of these receptors, 
termed TNF receptor-associated death domain (TRADD) and Fas-associated death 
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domain protein (FADD) respectively, bind and activate caspase 8 to form a complex 
called Death-Inducing Signalling Complex (DISC) (G. Chen & Goeddel, 2002). DISC 
then proceed to activate the executioner caspases, which results in cell death. The two 
apoptotic pathways are not always exclusive to these two initiation mechanisms, however. 
For example, when cytotoxic T cells and NK cells detect dysfunctional cells, such as 
infected cells or tumor cells, they release vesicles containing serine proteases such as  
granzyme B, and perforin (Everett & McFadden, 1999). Granzyme B passes through the 
cell membrane into the cytoplasm, which is facilitated by perforin. This cytolytic protein 
proceeds to cleave and activate caspases 3 and 8 to initiate the extrinsic apoptotic 
pathways and amplify the apoptotic cascade. Another mechanism in which both pathways 
get activated is through DIABLO/SMAC. This protein, like cytochrome c, is released 
from mitochondria following the activation of the intrinsic apoptotic pathway (Shi, 2001). 
Once released, it binds and inhibit the X-linked inhibitor of apoptosis protein (XIAP), an 
anti-apoptotic protein that binds to caspase 9 and blocks its activation. In this way, SMAC 
release from the mitochondria activates the ixtrinsic apoptotic pathway and enhance the 
programmed cell death response. 
 
During the process of cancer development, overcoming apoptosis is one of the crucial 
steps that are required for malignant transformation. To achieve this, several proteins 
involved in apoptosis are deregulated. For instance, overexpression of the antiapoptotic 
BCL2 is seen in lymphomas and small cell lung carcinomas (Kaiser et al., 1996; Otake et 
al., 2007). BCL2 overexpression serve to block apoptosis induction due to oncogenic 
activation by oncogenes such as MYC. Other mechanisms to block apoptosis frequently 
observed in different types of cancer is through p53 inactivation, which also protect the 
cells from p53- induced cell cycle arrest. Another mechanism in which cancer cells often 
use to block apoptosis is through the PI3K/AKT pathway. AKT/PKB blocks programmed 
cells death through different routes. Pro-apoptotic factor BAD has been shown to be 
phosphorylated and inactivated by AKT/PKB (Datta et. al, 1997). Additionally, 
AKT/PKB phosphorylate MDM2, resulting in the subsequent p53 degradation and 
inhibition of p53-dependent apoptosis (Maya et. al, 2001)( Zhou et.al, 2001). Moreover, 
AKT/PKB induce nuclear factor-kappa B (NFκB) indirectly by phosphorylating IκB 
kinase-α (IKK) and leading to the dissociation of NF-κBfrom its inhibitory partner IκBα 
(Kane et. al, 1999).  Once freed, NF-κB initiates the transcription of several genes 
including the anti-apoptotic factor BCL-XL and blocks apoptosis (Barkett et. al, 1999). 
Furthermore, AKT/PKB blocks p53-independent apoptosis by indirectly inhibiting the 
transcription of pro-apoptotic genes such as FasL and by the inhibition of the extrinsic 
apoptotic pathway (Brunet et. al, 1999)(Tang et. al, 1999). AKT/PKB also is reported to 
inhibit BIM and activate CREB, leading to BCL-2 induction (Pugazhenthi et. al, 2000). 
 
Another mechanism that is considered to serve to shield and block tumor formation is 
cellular senescence. Senescence is a fundamental process that is involved in different 
biological processes, such as wound healing and tissue repair, in addition to its role in 
blocking cancer. This cellular response is triggered by the dysregulation of the cell cycle 
and involve several negative, as well as positive regulators of the cell cycle machinery. 
Due to its importance for this thesis work, I will discuss senescence in detail in the next 





1.1.5   Cancer and the immune system 
 
The immune system is comprised of a variety of cells specialized in defending against 
pathogens, such as viruses and bacteria, but also plays an important role in cancer. The 
immune system is comprised of two arms, the innate and the adaptive immune systems. 
The innate immune system is our first line of defence against bacteria, viruses and foreign 
bodies, as well as cancer cells. It includes different cell types, namely granulocytes 
(basophils, eosinophils, neutrophils and mast cells), monocytes, macrophages, dendritic 
cells (DCs), as well as natural killer (NK) cells and innate lymphoid cells (ILCs). This 
arm of the immune system recognizes non-self molecule patterns called pathogen-
associated molecular pattern (PAMPs) and danger-associated molecular pattern 
(DAMPs). These molecular patterns include lipopolysaccharides and endotoxins which 
are identified by pattern recognition receptors (PRRs), such as Toll-like receptors (TLRs) 
and c-type lectin receptors found on the surfaces of the innate immune cells. PRR 
activation also induces the production of cytokines, such as IL-1α, which recruit more 
innate immune cells into the site (Janeway & Medzhitov, 2002). The innate immune 
response engages in phagocytosis of the detected pathogens, as well as infected cells, by 
macrophages, DCs and neutrophils. Macrophages and DCs belong to a group of cells 
specialised in antigen processing and priming called antigen-presenting cells (APCs), 
which process the phagocytosed and lysed pathogens for antigen presentation on their 
MHC class II receptors, an important process for the subsequent activation of the adaptive 
immune response. NK cells on the on the other hand are a type of cytotoxic lymphocytes 
that rely on a phenomenon called ¨missing-self recognition¨ of MHC class I antigens to 
identify and kill target cells. They express activating receptors, such as NKG2D, DNAM1 
and NKp46 and inhibitory receptors, such as killer cell Ig-like receptors (KIRs) on their 
surface. Upon contact with their target, NK cells bind to MHC class I complexes via their 
KIRs and to UL16 binding protein 1 (ULBP1) on target cells via NKG2D receptor. The 
presence of MHC class I and its binding to KIRs results in the inhibition of NK cell 
cytotoxic ability (Vivier et al., 2011). In virus-infected cells and cancer cells, MHC class 
I is downregulated, resulting in the activation of NK cells and the destruction of its target. 
Other cells of the innate immune system, such as basophils are involved in the recruitment 
of other immune cells and promotion of the inflammatory response. 
 
The second arm of the immune system is the adaptive immunity. Unlike the innate 
immune system, adaptive immunity is specific in its response. It relies on the 
identification of specific antigen to recognize its target, which results in taking longer 
time for initiation. This arm of the immune system is comprised of T cells, including CD8 
killer and CD4 helper T cells, as well as B cells, which includes effector B cells and 
memory B cells, that provides tailored response against their target. Adaptive immunity 
initiation is dependent on APCs from the innate immune system, as macrophage and DC 
presentation of antigen is a crucial step to trigger this part of the immune system. APCs 
migrate to the lymphoid organs, such as the lymph node, and present the antigens of the 
phagocyted pathogen/cell on their MHC class II molecules, which is recognized by CD4 
helper T cells, leading to their activation. The activated CD4 helper T cells in turn 
interacts with B cells displaying the same antigen on their MHC class II complexes, which 
triggers the proliferation of the CD4 T helper cells, as well as B cell proliferation and 
maturation into memory B cells and effector B cells. The effector B cells are responsible 
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for the production and secretion of antibodies that bind the pathogen or infected cells that 
display the appropriate antigen on their surface. The memory B cells on the other hand 
provide long term adaptive response and immunity for the same antigen, in case of future 
reinfection. In addition, NK cells recognize the target-bound antibodies through Fc 
receptor CD16 present on NK cells surface and proceed to eliminate the target cell, which 
is known as antigen-dependant cell cytotoxicity (ADCC). This process provides an 
example of the collaboration between the innate and the adaptive immune cells, in 
addition to the role of APCs in initiating the adaptive response. Aside from B cell 
activation, the CD4 helper T cells also secrete cytokines and chemokines, such as IL-2 
and interferon-γ (IFN-γ), that trigger CD8 killer T cell proliferation and the amplification 
of the immune response at the site. The CD8 killer T cells, also known as cytotoxic T 
lymphocytes (CTLs), bind its target cells via MHC class I complexes and proceed to 
induce apoptosis and eliminate their target (Paul, 2011; N. C. Smith, Rise, & Christian, 
2019).  
 
Beside its role in protecting against pathogens, the immune system can attack and 
eliminate tumor cells, protecting against cancer development. Albeit ongoing research is 
showing a complex dynamic interplay between the immune system and cancer cells. This 
has given rise to the hypothesis of immunoediting, which describes how cancer cells 
attempt to escape immunosurveillance, the process of monitoring and eliminating 
dysfunctional cells by the immune system, and eventually progress. This hypothesis 
emphasizes that the interaction between the immune system and cancer cells during tumor 
development consist of 3 distinctive states; elimination, equilibrium and escape 
(Schreiber, Old, & Smyth, 2011). Cancer cells are constantly adapting, through genetic 
or epigenetic mechanisms, to develop means to weaken the anti-tumor immune response 
and achieve immune escape. During the process, the balance between these phases 
determines the outcome between either tumor elimination and tumor escape and 
progression. 
 
Different immune cells subtypes have different effect on cancer cells, as some behave in 
an anti-tumor fashion and aid in its elimination, while some subtypes act as pro-tumor 
entities and protect the tumor for immune cells killing. For a better understanding, I will 
first discuss the anti-tumor side of the immune system, followed by the pro-tumor side. 
In the T cell compartment of the immune system, cytotoxic CD8 T cells are known to 
have an anti-tumorigenic function. They are one of the killer cells in the immune system, 
specialized in eliminating infected cells as well as cancer cells. During the process of 
tumorigenesis, cancer cells express “neoantigens”, which are products of genetic 
mutations during oncogenic activation. Upon death of cancer cells, these neoantigens are 
released into the surrounding tissue, where they are picked up by APCs, such as resident 
mature dendritic cells (mDCs) (Sánchez-Paulete et al., 2017). These cells process the 
antigens and present them on MHC class II molecules, and upon interacting with a naïve 
CD4 or CD8 T cells, activate them to become CD4 T helper or CD8 cytotoxic T cells 
(Binnewies et al., 2019; Broz et al., 2014). These CTLs then proceed to kill cells 
expressing these antigens together with MHC class I by inducing apoptosis via granzyme 
B or the death receptor, as I discussed in the previous section. Another subpopulation of 
the T cell compartment involved in anti-cancer immunity is the CD4 Th1 helper cells. 




and activate CD8 cytotoxic T cells (Umeshappa et al., 2009). These cells are also 
associated with recruitment of CD8 cytotoxic T cells via Th1 IFNγ-mediated CXCL9 and 
CXCL10 secretion by cancer cells (Peng et al., 2015). One other important player in the 
anti-tumor immunity response is Natural Killer (NK) cells. A common occurrence in 
cancer cells is the absentee of MHC class I molecules, a mechanism used to avoid 
detection by T -cells (Z. Wang et al., 2008). This allows NK cells to recognize and bind 
these cells, and to trigger apoptosis by releasing granzymes. Additionally, NK cells 
secrete chemoattractants, such as XCL1 and CCL5, which recruits DCs that stimulates 
CD8 cytotoxic T cells (Böttcher et al., 2018). Macrophages also play a role in anti-cancer 
immunity. Macrophages are monocyte-derived innate immune cells involved in clearing 
pathogen, cellular debris as well as cancer cells. These cells are further classified into 
M1-like and M2-like macrophages, based on the cellular markers displayed on the surface 
of these cells. The M1-like macrophages constitute the subset that is considered to aid 
against tumor development. These cells secret pro-inflammatory cytokines and 
chemokines, such as IL-12 and TNF-α, that attract other components of the immune 
system to the tumor tissue and enhance the anti-cancer immune response (Dorman & 
Holland, 2000; Olszewski, Groot, Dastych, & Knol, 2007). These cells are also capable 
of presenting antigens and aid in T cell activation for a robust immune response. 
Moreover, B-cells have been suggested to contribute to anti-tumor immunity through 
antibody-dependent cell-mediated cytotoxicity (ADCC) and the induction of NK and T 
cell response through IL-12- and IFNα/β-secretion (Guo & Cui, 2019). The myriad of 
anti-cancer immune cells highlights the importance of the immune system in the battle 
against cancer. 
 
On the other hand, there are several immune cell subtypes that protect cancer cells and 
promote cancer progression. One of the most important components of the pro-cancer 
immune response is a subpopulation of T cells, CD4 regulatory T cells (Tregs). These 
cells are mainly involved in the regulation of T cell immune response and mitigate their 
self-reactivity caused by autoimmune diseases, for instance. During tumorigenesis, 
cancer cells recruit Tregs and trigger their differentiation, perhaps through the secretion 
of C-C motif chemokine 22 (CCL22) and transforming growth factor beta (TGFβ) 
(Lippitz, 2013). Tregs serve to suppress T cell antitumor response through multiple ways. 
They deplete IL‐2, an important inducer of CD8 T cell proliferation, and inhibitory 
cytokines, such as TGF‐β and IL‐10, thereby resulting in the suppression of cytotoxic T 
cells (Collison et al., 2007; Setoguchi, Hori, Takahashi, & Sakaguchi, 2005; T. Takahashi 
et al., 1998). Tregs also express immune inhibitory receptors, such as cytotoxic T-
lymphocyte antigen-4 (CTLA-4) and lymphocyte activation gene-3(LAG-3), which 
further inhibits CTLs proliferation and their activation by APCs (Camisaschi et al., 2010; 
C. T. Huang et al., 2004). Additionally, Tregs contribute to CD39 and CD73 production, 
which are important for production of adenosine - a suppressor of Th1 helper and 
cytotoxic T cells (Maj et al., 2017). A subpopulation of macrophages also plays an 
integral role in pro-tumor immunity, demonstrating the plasticity of these cells during 
cancer development.  Unlike M1-like macrophages, these Tumor-Associated 
Macrophages (TAMs), belong to the M2-like anti-inflammatory subpopulation. It has 
been shown that M2-like macrophages suppress cytotoxic T cells through expression of 
the inhibitory molecules CTLA-4 and PD-1 (Mihic-Probst et al., 2020). Furthermore, 
monocytes, a precursor of macrophages, are recruited and differentiated into the M2-like 
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anti-inflammatory macrophages via the secretion of colony stimulating factor 1 (CSF-1) 
and CCL2 by cancer cells, highlighting the importance of monocytes in cancer 
development (Lewis & Pollard, 2006).  Beside promoting immune evasion, the pro-tumor 
role of M2-like TAMs extends to promotion of angiogenesis and metastasis, important 
hallmarks of cancer, by releasing VEGF-A, matrix metalloproteases and TGFβ (E. Y. Lin 
et al., 2006). Another entity involved in immune escape is myeloid-derived suppressor 
cells (MDSCs). MDSCs facilitate immune evasion by suppressing cytotoxic T cell 
function, tumor cell clearance by NK cells, recruitment of suppressive Tregs and 
promoting angiogenesis and metastasis (Ostrand-Rosenberg & Fenselau, 2018).  
Other immune cells involved in supporting tumor progression also include neutrophils, 
with multiple studies indicating a role in metastasis (Szczerba et al., 2019; Tao et al., 
2016). The increased knowledge about the contribution of these different immune cells 
to cancer progression instigated new interest in the molecular mechanisms of tumor 
immunology and inspired new promising therapies utilizing the immune system for 
cancer treatment. 
 
Figure 2: The concept of cancer immunoediting: elimination, equilibrium, and escape. Adopted from 
Schreiber RD, Old LJ, Smyth MJ. Cancer immunoediting: integrating immunity's roles in cancer 




During the past decade, several novel approaches for immunotherapies have been 
approved for treatment. For instance, the use of checkpoint inhibitors against CTLA-4 
and PD-1, has been approved for treatment of malignant melanoma. These inhibitors 
block cytotoxic T cell inactivation via these molecules resulting in tumor elimination. 
Another strategy involves the use of Tumor Infiltrating Lymphocytes (TILs), that are 
harvested from patients. Once harvested, they are activated and propagated in vitro by IL-
2 stimulation and reintroduced into the patient, where they actively attack and help 
eliminate the tumor. Moreover, the use of engineered T cells known as Chimeric Antigen 
Receptor-T cells (CAR-T cells) was approved in 2017 for the use in haematological 
malignancies. Similar to TILs, this strategy requires the purification of T cells, which are 
then expanded by stimulation with IL-2 and CD3. Following their expansion, the T cells 
are genetically modified to express chimeric antigen receptors against the patient's tumor 
antigens utilizing retroviral vectors and CRISPR/Cas9 technology. The cells are then 
administered to the patient, where they can kill cancer cells expressing these antigens. 
CAR-T cell treatment showed promising results in treating diffuse large B-cell lymphoma 
and leukemia. Despite their success in the treatment of several types of tumors, some 
patients did not benefit from this treatment because of weak immune response. In addition, 
the efficiency of CAR-T cell treatment on tumors with low immunogenicity was limited. 
Moreover, adoptive cell therapy, including TILs and CAR-T cells, was not as successful 
in treating solid tumors, mainly due to the highly immunosuppressive tumor 
microenvironment that negatively affected their activity and survival (M. Martinez & 
Moon, 2019). This suggests that these immunotherapies still suffer from limitations and 
challenges, requiring more knowledge and research in the field of cancer immunology.     
  
1.1.6   Lung cancer  
 
Due to its relevance to this thesis, I will briefly discuss lung cancer in this section. Lung 
cancer is the global leading cause of cancer-related deaths. According to statistics from 
the world health organization (WHO) approximately, a total of 2 million diagnosed cases 
and 1.76 million deaths were recorded in 2018 (World Health Organization, 2019). The 
median 5-survival of lung cancer is 10-20% and is heavily dependent on stage of 
diagnosis. Lung cancer is classified into two major subtypes: non-small cell lung cancer 
(NSCLC) and small-cell lung cancer (SCLC). NSCLC comprise most lung cancer 
patients and is sub-divided into adenocarcinoma, squamous cell carcinoma and large cell 
carcinoma (Inamura, 2017), Meanwhile, SCLC account for 15 % of all lung cancer 
patients. NSCLC is generally less aggressive and is characterized with a lower 
proliferative index and metastatic rate than observed in than SCLC. The most frequent 
driver mutations hit KRAS (20-50%) and EGFR (10-35%), whom are usually mutually 
exclusive ((Herbst, Morgensztern, & Boshoff, 2018; Massó-Vallés, Beaulieu, & Soucek, 
2020). In addition, other driver mutations have been identified, such as BRAF (1-5%), 
ERBB2/3 (10-15%), NRAS (1%), HRAS (1.6%), AKT1/2/3 (1–2%), and amplifications 
in MYC (33%), MET (2–4%), FGFR1 (20%), and chromosomal rearrangements in ALK 
(3-7%) and ROS1 (1-2%) (Q. G. Zhu, Zhang, Ding, He, & Zhang, 2017). Additionally, 
inactivation of p53, PTEN, ATM, CDKN2A, and RB, among others (Herbst et al., 2018; 
Iwakawa et al., 2011; Schaub et al., 2018). For patients with EGFR-mutated NSCLC, the 
treatment consists of tyrosine kinase inhibitors as the first-line treatment, with disease 
relapse unfortunately observed in most patients (Ricciuti et al., 2016). Targeted therapies 
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for KRAS are not yet available and patients undergo standard platinum-based 
chemotherapy as their first line treatment.  
 
The SCLC subtype is very aggressive, with a 5-year medial survival of 1-5% and is 
characterized with a higher proliferation index, rapid metastatic onset and neuroendocrine 
phenotype (Travis, Brambilla, Burke, Marx, & Nicholson, 2015). SCLC is associated 
with tobacco smoking, displaying a high mutational rate, and associated with loss-of-
function mutations in important tumor suppressor genes TP53 and/or RB in the majority 
of the patients (Wistuba, Gazdar, & Minna, 2001). Similar to NSCLC, SCLC is also 
driven by the different oncogenic mutations. Around 20-40% of SCLC cases show 
activating mutations in the PI3K pathway, while 20 % exhibit amplification or 
upregulation of MYC family members, with around 9-10 % MYCL, 6% MYC or 4% 
MYCN (George et al., 2015; Mollaoglu et al., 2017; Semenova, Nagel, & Berns, 2015). 
Other known alterations include NOTCH, BCL2 and mutations in histone modifiers, such 
as CREBBP and EZH2 (Jiang, Sato, Kuwao, & Kameya, 1995; Semenova et al., 2015). 
Unfortunately, no targeted therapies are available for SCLC yet, the standard treatment 
for SCLC consists of radiotherapy and platinum-based chemotherapy, similar to KRAS-
driven NSCLC, with nearly all patients relapse due to acquired resistance to 
chemotherapy (Alvarado-Luna & Morales-Espinosa, 2016; Wagner et al., 2018). When 
it comes to immune therapy, anti-PD-1/PD-L1 treatment have shown significant 
improvement in both lung cancer subtypes, with over 50% and 39% response in NSCLC 
and SCLC patients, respectively (Calles, Aguado, Sandoval, & Álvarez, 2019; Doroshow 
et al., 2019). These treatments have been approved for first line use in both NSCLC and 
SCLC. Nevertheless, more work is needed to improve treatments and diagnosis for lung 
cancer patients, as well as the development of new therapeutics to achieve better 
outcomes.  
 
1.1.7   Acute myeloid leukemia 
 
Due to the relevance to thesis work, I will also have a brief introduction about acute 
myeloid leukaemia (AML) in this section. AML is a type of haematological malignancy 
that arises in in the myeloid linage as immature progenitors resembling myeloblasts, 
which are unable to differentiate into functional blood cells. The accumulation of AML 
precursors in the blood system results in deficiencies in the production of several innate 
immune cell types, red blood cells and platelets. AML is a heterogeneous disease, 
consisting of several subtypes based on genetic and histopathological features. This 
includes AML with recurrent genetic abnormalities, therapy-related AML, 
myelodysplasia-related AML, AML with NPM1 mutation and AML with biallelic 
mutation of CEBPA, to name a few (Arber et al., 2016). The risk stratification of AML 
classifies patients into three main risk groups; favourable, intermediate, and adverse, 
based on their cytogenetics and molecular profile. AML is driven by many different 
oncogenic factors, including mutations in FMS-like tyrosine kinase 3 intracellular 
tyrosine kinase domain (FLT3-TKD), Runt-related transcription factor (RUNX1), DNA 
methyltransferase 3 alpha (DNMT3A), Ten-eleven translocation methylcytosine 
dioxygenase 2 (TET2), CCAAT/enhancer-binding protein alpha (CEBPA), 
nucleophosmin (NPM1), BCR-ABL1 fusion and mutant p53, many others (Döhner et al., 




types of AML, as well as chronic myeloid leukemia (CML) and lymphomas. Examples 
of this are MYC deregulation in chromosome 8 trisomy in AML, or through the 
BCR/ABL translocation and activation in CML or indirectly as a consequence of 
activation of other oncogenic drivers, such as FLT3 (Jones et al., 2010; K. T. Kim et al., 
2007; Sawyers, Callahan, & Witte, 1992). Moreover, MYC overexpression and 
deregulation in human leukaemia’s is linked to poor prognosis and survival (Ohanian et 
al., 2019; Yun et al., 2019). These many different drivers of AML result in a heterogenous 
patients’ profile, with different and variable responses to the treatments available. 
 
The current long-term survival for AML is 40-45% in patients younger than 60 years and 
20% for patients over the age of 60 (Tallman, Gilliland, & Rowe, 2005). Despite the 
heterogeneity in the molecular drivers of AML, the first standard treatment is usually an 
induction chemotherapy with general DNA synthesis inhibitors such as cytosine 
arabinoside (ara-C) and DNA-damaging agent anthracycline, with 60-70% complete 
remission in young patients, and 38-60% in older patients over the age of 70 (Döhner et 
al., 2017). This is followed by consolidation therapy, a second round of ara-C treatment, 
to eliminate remaining cancer cells. Patients with resistant AML subtypes, such as 
patients with p53 mutations, are treated with hypomethylating agents decitabine or aza-
cytidine instead of ara-C and anthracycline (Quintás-Cardama et al., 2012). Following the 
consolidation therapy, patients might undergo bone marrow transplantation surgery 
(Popat et al., 2012). However, a few new targeted therapies have shown enhanced survival 
and specificity with lower toxicity in the past decade. For instance, FLT3 inhibitors, such 
as crenolanib and gilteritinib, have shown improved potency with considerably less 
toxicity compared to standard treatment (Döhner et al., 2017). Moreover, inhibition of 
SIRT1 protein expression in human FLT3-ITD AML LSCs has been proposed to improve 
treatment outcomes and remission in patients (L. Li et al., 2014). Additionally, IDH 
inhibitors, such as enasidenib, promoted differentiation, halted tumor proliferation and 
provided better complete remission rates, and were granted FDA approval for clinical use 
(Stein et al., 2019; Yen et al., 2017). Lastly, p53 reactivator, APR-246, has shown great 
promise in primary AML cells and currently in phase III clinical trials for the treatment 
of p53-mutated malignancies, including AML (Ali et al., 2016; Deneberg et al., 2016). 
These new therapies improve the quality of life for the patients and provide more robust 
and effective AML treatments, yet more advancement is needed.   
 
1.2   Senescence 
 
In this chapter of this thesis introduction, I will discuss cellular senescence, including 
mechanisms of senescence induction, its molecular features, its effect on the immune 
response and its potential as a therapeutic strategy against cancer. 
 
1.2.1 Senescence induction and markers 
 
Senescence is a state of permanent growth arrest, in which the cell does not respond to 
growth stimuli. It is a cellular process that is often triggered in response to different types 
of stress signals. Senescence was first described as a manifestation of cellular aging in a 
process called replicative senescence. In this case, cells undergo senescence due to the 
shortening of the telomeres, which are repetitive nucleotides sequences situated at the 
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ends of each chromosome. This shortening is a consequence of accumulative cellular 
growth cycles (Sfeir & de Lange, 2012) due to the inability of DNA polymerase to 
synthesize new DNA strand starting from the 3’ end. Instead, RNA primers are used to 
initiate DNA replication of the lagging strand. These RNA primers are then degraded, 
resulting in the shortening of the DNA at the end of the chromosomes, eventually 
resulting in the erosion of the protective telomere caps at chromosomal ends. In addition, 
it can be triggered in response to many stimuli, other than telomere erosion,  such as 
oncogene activation, oxidative stress, DNA damage and even as an effect of global 
relaxation of the chromatin, caused by histone deacetylase inhibitors and thereby block 
expansion of damaged cells (Munro, Barr, Ireland, Morrison, & Parkinson, 2004; 
Nakamura et al., 2008).  
Senescence plays a role in cellular processes other than aging. Senescence has also been 
shown to play an important role in other processes in the life span of an organism, such 
as wound healing, regeneration and development. Studies in mouse models demonstrated 
that inhibition of senescence induction or the elimination of senescence cells delayed 
wound healing and increased the formation of fibrotic scars in the injured tissue (Demaria 
et al., 2014; Jun & Lau, 2010). It also has been shown that senescent cells suppress cell 
reprogramming during induced pluripotent stem cell generation by Yamanaka factors 
(OCT4, SOX2, c-MYC, and KLF4), indicating a role for senescent cells in regulating 
stemness (Hong et al., 2009). Additionally, senescence plays a role in embryogenesis, 
neurodegenerative diseases, diabetes and other cellular mechanisms and diseases. These 
observations demonstrate the importance of cellular senescence in different biological 
processes, ranging from aging, development, tissue repair to pluripotency. Here, I will 
focus on senescence induction via oncogene activation, a process called oncogene-
induced senescence (OIS). In the past two decades, numerous studies have demonstrated 
that overexpression of oncogenes can trigger senescence. Early studies have revealed that 
overexpression of a mutant constitutively active form of HRAS induced senescence when 
introduced in normal cells (Serrano, Lin, McCurrach, Beach, & Lowe, 1997). Activation 
of RAS leads to replicative stress due to extensive cellular replication cycles and 
production of oxygen-reactive species (ROS). Later, KRAS, NRAS, BRAFV600E, MYC, 
PAK4 and E2F overexpression were reported to trigger senescence in vitro and in vivo 
(Braig et al., 2005; Cammarano, Nekrasova, Noel, & Minden, 2005; Collado, Blasco, & 
Serrano, 2007; Dankort et al., 2007; Lazzerini Denchi, Attwooll, Pasini, & Helin, 2005; 
Michaloglou et al., 2005). Senescence induction has also been observed in response to 
genetic deletions of tumor suppressors, such as PTEN, von Hippel–Lindau (VHL) and 
neurofibromatosis type 1 (NF1), partly due to loss of normal regulation of cellular 
processes by these tumor suppressor protein pathways (Z. Chen et al., 2005; Courtois-
Cox et al., 2006; Young et al., 2008). The stress signals generated from these events lead 






While senescence can be triggered by many different stimuli, it is mainly induced via the 
activation of the following three main pathways; pRB/p16INK4A, ARF/p53/p21CIP1 and 
DNA damage response (Collado & Serrano, 2010; Larsson, 2011). For instance, cellular 
stress induced by oncogene activation, such as RAS, usually leads to the induction of the 
p16INK4A tumor suppressor protein (Serrano et al., 1997). p16INK4A blocks the CDK4/6-
cyclin D complex, leading to the activation of pRB. Activated pRb binds and inhibits E2F, 
suppressing the transcription of its target genes, such as cyclin E1, by recruitment of DNA 
methyltransferases and histone deacetylases (Mason, Jackson, & Lin, 2004). Additionally, 
pRB triggers the degradation of SKP2 by E3 ligase complexes, leading to an increase in 
p27KIP1 protein levels (Binné et al., 2007). These effects result in the termination of the 
cell cycle and impose a senescent state. p53-dependent senescence induction is triggered 
by another tumor suppressor protein encoded from the INK4A/CDKN2A locus, called 
ARF. Excessive signalling of oncogenes such as RAS triggers induction of ARF. The 
Figure 3: Different signals and pathways triggering senescence, and some characteristics of senescent 
cells. Adopted from Di Micco R, Krizhanovsky V, Baker D, d'Adda di Fagagna F. et al., Cellular 




accumulation of ARF leads to the phosphorylation of MDM2, which in turn liberates p53 
from degradation and enhances its protein levels (Abida & Gu, 2008). p53 in turn 
activates the expression of p21CIP1, resulting in the inhibition of CDK2, termination of 
DNA synthesis, and triggering senescence (Wierød et al., 2008). The third route of 
senescence induction is initiated through the DNA damage response. Sensor mechanisms 
within the cell detect DNA damage, a consequence of replicative stress and/or ROS 
production accumulated due to extensive growth signalling by oncogenes (Bartkova et 
al., 2006; Di Micco et al., 2006; Mallette, Gaumont-Leclerc, Huot, & Ferbeyre, 2007). 
DNA damage triggers the activation of two proteins involved in the DNA damage 
response mechanism, serine/threonine kinases ATM and ATR (J. Smith, Tho, Xu, & 
Gillespie, 2010). These biological sensors are activated in response to double-strand 
breaks and single-strand breaks, respectively. Once activated, ATM and ATR 
phosphorylate and activate their downstream effectors, Chk2 and Chk1. Chk2 
phosphorylates and activates p53, leading to p21CIP1 induction and senescence (Bartek & 
Lukas, 2007; Campisi, 2013; d'Adda di Fagagna, 2008). 
 
Identification of senescent cells rely on the detection of different senescence markers. 
Senescent cells usually display high levels of β-galactosidase activity, which often 
referred to as senescence-associated β-gal (SA β-gal) activity, which is the most well-
known marker of senescence. They also increase in size and become flattened, and often 
dense heterochromatin regions, termed Senescence-Associated Heterochromatin Foci 
(SAHF) appear in the nucleus (Narita et al., 2003). Other features of senescent cells 
include high metabolic activity, and as mentioned above induction of CDKIs, p16INK4A 
and p21CIP1 and loss of proliferative markers, such as Ki-67 and depletion of nuclear 
lamina Lamin-B1 (LMNB1) (reviewed in (Hernandez-Segura, Nehme, & Demaria, 2018). 
But perhaps the most intriguing characteristic of senescent cells is the secretion of a 
variety of cytokines, chemokines, extracellular matrix modifiers and proteases, a process 
called senescence-associated secretory phenotype (SASP). This feature contributes to 
many different aspects of cancer, both negatively and positively, making it perhaps the 
most controversial characteristic of senescent cells, and therefore I will discuss this 
phenomenon in more detail below. Importantly, expression of various senescence 
markers is often context- and tissue-dependent, and all of these are not necessarily 
observed in all cells undergoing senescence. Worthy of note, some markers are also 
present in non-senescent cells during certain conditions, for instance, SA β-gal positive 
staining is not only exclusive for senescent cells, as some non-senescent cells can display 
high lysosomal activity. In addition, quiescent cells can display a reduction in 
proliferation markers and induction of CDKI expression. As a result, to determine if a 
cell is senescent, one cannot rely on a single marker, but needs to examine several of these 
markers. 
 
1.2.2 Senescence-Associated Secretory Phenotype (SASP) 
 
The SASP phenomenon is complex and is manifested by the secretion of a wide variety 
of growth factors, proteases and immune modulators, such as TGF-β, MMP3 and IL-6, 
that are involved in many cellular processes (Acosta et al., 2008; Kang et al., 2011). SASP 
is regulated at different levels; transcription of SASP genes is triggered by stresses such 




which in turn lead to the induction of p38 MAPK, NF-κB and CCAAT enhancer-binding 
protein β (C/EBPβ) among others factors (Freund, Patil, & Campisi, 2011). In addition to 
transcriptional regulation, p38MAPK enhances MAPK-activated protein kinase 2 (MK2) 
activity, leading to mRNA stabilization of different SASP components by heat shock 
protein 27 (HSP27) and AU-rich element RNA-binding protein 1 (AUF1) (Alspach et al., 
2014). Moreover, mTOR stabilizes and protect MK2 from degradation, which enforces 
the SASP signalling in senescent cells (Herranz et al., 2015). Recent studies have also 
demonstrated that DNases are downregulated in senescent cells, allowing for the 
accumulation of cytosolic DNA fragments and triggering the activation of the cyclic 
GMP–AMP synthase (cGAS)–stimulator of interferon genes (STING) pathway (Glück et 
al., 2017; A. Takahashi et al., 2018). In turn, the cGAS–STING results in the activation 
of the NF-κB pathway, and subsequently, to SASP expression (Dou et al., 2017). Unlike 
NF-κB and C/EBPβ, it has been shown that NOTCH1 can prevent pro- inflammatory 
SASP cytokine secretion through induction of C/EBPβ degradation in senescent 
fibroblasts (Hoare et al., 2016). Finally, several epigenetic factors are also involved in 
SASP regulation. Studies in senescent human fibroblasts showed that inhibitors of histone 
deacetylase (HDAC) led to the activation of several SASP factors, even in the absence of 
DDR, suggesting a role for HDACs in suppressing SASP expression (Pazolli et al., 2012). 
Similarly, the chromatin modifier EZH2 has also been reported to suppress production of 
SASP (Ito, Teo, Evans, Neretti, & Sedivy, 2018). Although SASP is usually part of the 
senescence response, it is worth mentioning that the ectopic activation of p16INK4A or 
p21CIP1 does not lead to SASP activation (Coppé et al., 2011). This observation shows 
that SASP induction is context-dependent and involves different mechanisms that are not 
fully understood yet. 
 
Giving the large spectrum of factors that are part of the SASP, the effects resulting from 
this production are diverse and involve many pro- and anti-tumor aspects. For example, 
IL-6 secreted by senescent cells suppress tumor growth and maintain the senescent 
phenotype triggered by RAS induction (Kuilman et al., 2008). It has also been shown that 
IL-6 induces signal transducer and activator of transcription 3 (STAT3) expression in 
human fibroblasts, promoting reactive oxygen species (ROS) production and 
subsequently senescence induction in a paracrine manner (Nelson, Kucheryavenko, 
Wordsworth, & von Zglinicki, 2018). TGF-β and IL-1α can induce senescence in nearby 
cells, as well as reinforce senescence through a feedback loop mechanism (Acosta et al., 
2013; Acosta et al., 2008; Orjalo, Bhaumik, Gengler, Scott, & Campisi, 2009). 
Additionally, chemokine (C–X–C motif) ligand 1 (CXCL1) and CXCL2 has been 
reported to enforce the senescent state in an autocrine manner (Acosta et al., 2008). More 
recently, Ruscetti et al. demonstrated that pro-angiogenic factors within SASP enhanced 
drug delivery and immune clearance of senescent cancer cells in a model of Pancreatic 
Ductal Adenocarcinoma (PDAC), potentially opening for new cancer treatment strategies 
utilizing SASP (Ruscetti et al., 2020). These are some of the observations suggesting a 
role of SASP components in halting tumorigenesis, but the SASP may also have pro-
tumorigenic effects. For instance, IL-6 has been reported to contribute to tumor 
proliferation in breast, lung and prostate cancer models (Di et al., 2014; Hartman et al., 
2013; Rojas et al., 2011; Song, Rawal, Nemeth, & Haura, 2011). Similarly, CXCL1 
promoted proliferation in a model of esophageal tumors (B. Wang, Hendricks, 
Wamunyokoli, & Parker, 2006). Moreover, SASP has been implicated in epithelial-
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mesenchymal transition (EMT) and metastasis. For instance, loss of hyaluronan and 
proteoglycan link protein 1 (HAPLN1) in aged fibroblasts was shown to promote tumor 
cell motility and metastasis (A. Kaur et al., 2019).  Additionally, persistent SASP can 
induce endothelial cell proliferation and angiogenesis through VEGF secretion (Coppe et. 
al, 2006)(Oubaha, 2016). SASP may also contribute to epithelial-mesenchymal transition 
(EMT) and tumor invasion through the secretion of CXCL-1 and matrix metalloproteases 
3 (MMP3) (Coppé, Kauser, Campisi, & Beauséjour, 2006; Laberge et al., 2012; D. Liu 
& Hornsby, 2007). In summary, SASP can have quite diverse and even contradicting 
effects on tumor cells and on tumor-promoting cells in the microenvironment. In addition, 
SASP contributes to different aspects of tumor immunity. In the rest of this chapter, we 
will discuss the different effects exerted by SASP on the immune system and how this 
potentially can be utilized for new treatments strategies. 
 
 
1.2.3 Senescence and Immunity 
 
Besides cell cycle arrest, senescent cells engage in modulating the immune response in 
affected tissues. The immune modulatory effects are manifested by the changes in 
senescent cells as well as the secreted immune factors which are part of the SASP, which 
play different roles in regulating the immune response, positively as well as negatively. 
The different chemokines and cytokines secreted by the senescent cells create an immune 
inflammatory environment and results in the recruitment and activation of immune cells, 
such as macrophages, T cells and natural killer cells. Different studies have shown that 
Figure 4: The pro- and anti-tumorigenic properties of the senescence-associated secretory phenotype 
(SASP). Adopted from Lau L, David G. et al., Pro-, and anti-tumorigenic functions of the senescence-




the recruitment of these immune cells can be beneficial. A study by Iannello et al. using 
a HRAS-driven hepatocarcinoma tumor model showed that the reintroduction of p53 led 
to senescence induction, elevated activation marker NKG2D expression on NK cells, 
infiltration of innate immune cells and tumor clearance (Iannello, Thompson, Ardolino, 
Lowe, & Raulet, 2013). NK cell recruitment and sensitization of senescent cells to NK 
cells killing has been reported by other studies. For instance, senescent cells can express 
UL16 binding protein 1 (ULBP1) and ULBP2, which can activate the cytotoxic function 
of NK cells (Textor et al., 2011). In addition, pharmacological induction of senescence 
by the CDK4/6 inhibitor palbociclib and the MEK inhibitor trametinib in a 
KRASG12D/p53-null lung cancer mouse model resulted in the induction of intercellular 
adhesion molecule-1 (ICAM-1), ULBP2 and MHC class I polypeptide-related sequence 
A (MICA) on tumors cells in a TNF-dependent manner (Ruscetti et al., 2018). These 
changes led to the recruitment of NK cells and reduction in the tumor mass. The ability 
of senescent cells to recruit NK cells is attributed to the secretion of SASP factors, such 
as CCL2, CCL5 and IL-15, highlighting some of the anti-tumor effects of SASP. The 
immune-modulatory effect of SASP factors extends also to other immune cells. SASP-
mediated recruitment of immature myeloid cells and their subsequent differentiation into 
macrophages by CCL2 was reported in a NRASG12V-driven hepatocellular carcinoma 
model (Eggert et al., 2016). Similarly, senescence induction by p53 promoted M1-like 
macrophages differentiation and lead to tumor regression in another hepatocarcinoma 
mouse model (Lujambio et al., 2013). Furthermore, a study by Kang et al. demonstrated 
that SASP factors can facilitate anti-tumor immunity through the adaptive compartment 
of the immune system. Using the NRASG12V liver cancer model, they showed infiltration 
of CD8 cytotoxic T cells and CD4 helper T cells into the senescent tumors in an ARF-
independent manner, which led to clearance of senescent cells (Kang et al., 2011). 
However, the elimination of the tumor cells was mainly carried by cells of the innate 
immune cells, albeit this was dependent on the recruitment and activation of the T cell 
population.   
Although SASP is involved in the recruitment of immune cells and tumor elimination, 
the response is context-dependent, and influenced the molecular makeup of the tumors as 
well as the tissue type.  In the study by Eggert et al. mentioned above, it was shown that 
the transplantation of tumor cells into wildtype mice harbouring senescent hepatocytes 
led to fast tumor progression compared to transplanted mice lacking the senescent cells, 
suggesting that SASP factors secreted by the tumor cells suppressed the immune response. 
This involved CCL2-dependent recruitment of myeloid-derived suppressor cells 
(MDSCs) that blocked NK cell activation (Eggert, 2016). Another example of a 
heterogeneous SASP response is seen with CXCR2. CXCR2 was shown to inhibit 
proliferation and trigger senescence in KRAS-transformed fibroblasts, while it led to the 
recruitment of immune suppressive MDSCs in a RAS-driven PDAC model (Acosta et al., 
2008(Steele et al., 2016). In addition, SASP-mediated immunomodulation was affected 
by p53 and PTEN status within the tumor population. For instance, the activation of NK 
cells by immune-related receptors induced on senescent cells, such as ULBP2, was lost 
upon p53 inactivation (Lujambio et al., 2013)(Iannello et al., 2013). Similar to p53 loss, 
PTEN-deficient senescent tumors were characterized by infiltrating MDSCs, resulting in 
immune suppression and tumor progression (Di et al., 2014;(Toso et al., 2014). This effect 
was shown to be dependent on JAK2/STAT3 signalling, as the inhibition of this pathway 
resulted in tumor regression and immune activation, uncovering an important role for 
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JAK2/STAT3 pathway in mitigating the immunomodulatory effect of SASP. Finally, 
SASP factors, such as VEGFA, can contribute to maturation of immune-inhibitory Treg 
cells, adding another possible mechanism in which SASP can stimulate pro-tumor 
immunity (Terme et al., 2013).  
 
 
These observations suggest that SASP can act as a double-edged sword, where in one 
hand it can contribute to immune activation and tumor elimination, and on the other 
hand to immunosuppression and tumor evasion. Nevertheless, this characteristic of 
senescent cells can possibly be exploited to combine immune therapy alongside 
senescence induction in tumor cells, an approach yet to be explored further. 
 
1.2.4 Pro-senescence therapy 
 
The ability to block tumor proliferation through senescence induction in different models 
has led to the idea of utilizing senescence as anti-cancer therapy – a concept known as 
pro-senescence therapy. This approach relies on the use of treatments that result in 
induction of senescence. An example of this are CDK4/6 inhibitors. As discussed in 
section 1.1.3, CDK4/6 has a crucial role in the inactivation of pRB and cell cycle 
progression, while its inhibition leads to withdrawal from the cell cycle and senescence 
induction. Several CDK4/6 inhibitors have been shown to induce senescence in different 
cancer cells. For instance, treatment with palbociclib resulted in senescence induction in 
melanoma, breast cancer and hepatocellular carcinoma among others (Bollard et al., 
Figure 5:  Different roles of SASP factors in tumor immune surveillance. a) Anti-tumor immune cell 
activation. b) Pro-tumor immune cell activation. Adopted from Faget DV, Ren Q, Stewart SA. Et al., 





2017; Goel et al., 2016; Yoshida, Lee, & Diehl, 2016), while abemaciclib induced 
senescence and blocked tumor development in xenografts of breast and lung cancer 
models (Gong et al., 2017; Torres-Guzmán et al., 2017). The successful use of 
senescence-inducing cell cycle inhibitors in several cancer clinical trials lead to FDA-
approval for patient use of these drugs and paved the way for the possibility of pro-
senescence therapy. Induction of senescence in cancer cells can also be achieved by 
targeting other senescence regulators. For example, DNA methyltransferases (DNMTs), 
such as 5-Aza-2-deoxycytidine (5-aza), and HDAC inhibitors, such as suberoylanilide 
hydroxamic acid (Vorinostat), have been shown to disturb tumor proliferation and induce 
senescence in different cancer cell lines, including MCF7 (breast cancer), U2OS 
(osteosarcoma), HCT116 (colon cancer) as well as in T cell lymphoma patients (Almeida 
et al., 2017; Putri, Widodo, Sakamoto, Kaul, & Wadhwa, 2017; Xu, Perez, Ngo, Gui, & 
Marks, 2005). The induction of senescence by these drugs is possibly due to loss of 
promoter hypermethylation and induction of p16INK4A and activation of the DDR 
signalling. Similarly, p53 reactivating drugs can be used in a pro-senescence therapy 
strategy (Iannello et al., 2013; Xue et al., 2007). 
 
Another aspect of the pro-senescence therapy is the secreted SASP factor’s abilities to 
induce remodelling of the microenvironment and anti-tumor immunity. This feature of 
SASP was demonstrated in many systems, which we mentioned in the previous section. 
SASP can promote vascular normalization in the tumor area, enhancing anticancer drug 
delivery and immune cell infiltration to the tumor area (Ruscetti et al., 2020). Activation 
of NK cells against senescent tumor cells in different settings was achieved by the re-
activation of p53, pharmacological inhibition of cell cycle regulators or activation of DDR 
by DNA-damaging agents, such doxorubicin (Iannello et al., 2013; Ruscetti et al., 2018; 
Soriani et al., 2009). Anti-tumor M1-like macrophages can also contribute to pro-
senescence therapy response and clear senescent cells from tissues (Lujambio et al., 2013). 
Other immune cells triggered by SASP include adaptive immune cells, such as T cells, 
which can be part of this therapeutic approach. In addition to the recruitment of CD8 
cytotoxic and CD4 helper T cells demonstrated in the hepatocellular carcinoma model by 
Kang et al., the dual pharmacological blockade of MDM2 and AURKA in a B16F0 
melanoma model induced cellular senescence in the tumor cells, accompanied by CCL5 
secretion (Vilgelm et al., 2015). Re-activation of senescence by this treatment was 
characterized by recruitment of T cells, as well as other leukocytes, into the tumor area 
and aided in tumor clearance.  
 
The immunomodulatory effects of SASP have also been used in combination with 
immunotherapies to achieve eradication of cancer cells. In addition to the recruitment of 
immune cells by SASP, senescence induction can possibly sensitize ’immunologically 
cold’ cancers to immune therapy, as in the case of the induction of ULBP1 & 2 expression 
in senescent cells mentioned in the previous section. For instance, a study by Vilglem et 
al. showed a robust killing of tumor cells by activated TILs following senescence 
induction through AURKA inhibition in melanoma cells (Vilgelm et al., 2016). This 
enhanced TIL killing efficacy was dependent on CCL5 as part of the SASP secretome. 
The immune enhancing properties of pro-senescence therapy were also observed in other 
studies, utilizing checkpoint inhibitor immunotherapies, further supporting the approach 
of combining pro-senescence and immune therapies (Hu-Lieskovan et al., 2015)Goel et 
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al., 2017). However, SASP can also have pro-tumor tumors effects by blocking anti-
tumor immunity. To counter this, new strategies has been proposed to try to modulate the 
SASP response to inhibit its pro-tumor components. As an example, the use of docetaxel, 
a mitotic spindle inhibitor, together with a CXCR2 antagonist was shown to induce 
senescence in PTEN-null mouse prostate tumour cells while abrogating CXCR2-driven 
Gr-1+ MDSC infiltration in vivo (Di Mitri et al., 2014). Inhibiting the SASP-regulatory 
JAK2/STAT3 pathway was also evaluated in this model. Docetaxel treatment in 
combination with pharmacological inhibition of JAK2 by NVP-BSK805 led to the 
attenuation of the SASP immunosuppressive signalling and enhanced the recruitment of 
T, NK and B cells into the tumor, resulting in tumor regression (Toso et al., 2014). The 
modulation of the SASP response in these studies while retaining the cell cycle arrest, 
provided a proof of concept that targeting certain SASP regulators, such as NF-κB, 
p38/MAPK, HDACs and SASP factors like IL-1 and IL-6 enhance the pro-senescence 
therapy outcome.  
 
Aside from SASP modulation, the prospect of targeted elimination of senescent cells by 
pharmacological inhibitors targeting vulnerabilities in senescent cells is emerging as a 
promising strategy in cancer treatments. This idea emerged after studies have 
demonstrated that senescent cells can be targeted and removed (Y. Zhu et al., 2015). 
Chang et al. subsequently demonstrated the senolytic ability of the pan-BCL2 inhibitor 
ABT-263 (Navitoclax) in mouse models used for aging studies (Chang et al., 2016). Since 
then, navitoclax has been used in many cancer studies, including breast cancer, ovarian 
cancer and small lung cancer, showing promising results for apoptosis induction and 
eradication of senescent cancer cells (Fleury et al., 2019; Nakajima et al., 2016). A recent 
study by Galiana et al. demonstrated that the treatment with navitoclax, encapsulated in 
targeted nanoparticles, following senescence induction by palbociclib resulted in 
reduction of metastases, inhibition of tumor growth, with minimal toxicity in a triple 
negative breast cancer (Galiana et al., 2020). This work further demonstrates the potential 
of this strategy in combating cancer through pre-senescence therapy. Other BCL-2 
inhibitors, such as obtoclax, showed similar effects as navitoclax when combined with 
the bromodomain and extraterminal motif (BET) inhibitor JQ1 in breast cancer (Gayle et 
al., 2019).  The senolytic effect was not restricted to anti-apoptotic inhibitors; elimination 
of senescent cells has been achieved using mTOR inhibitors, DNA replication inhibitors 
as well as using HDAC inhibitors in different cancer models (Demaria et al., 2017; 
Samaraweera, Adomako, Rodriguez-Gabin, & McDaid, 2017; C. Wang et al., 2019). 
Additionally, targeting proteins and enzymes involved in metabolism, exploiting the high 
metabolic activity of senescent cells, have led to synthetic lethal effects and elimination 
of senescent cells (Dörr et al., 2013; Kaplon et al., 2013; Wiley & Campisi, 2016). The 
list of senolytic drugs also extends to non-cancer treatments and natural active compounds, 
such as type 2 diabetes drug metformin and fisetin, which have the ability to induce 
cytotoxic effects in senescent cells (Moiseeva et al., 2013; Yousefzadeh et al., 2018). 
Finally, another demonstration of the potential of combining pro-senescence therapy with 
immunotherapies to achieve a senolytic effect was demonstrated in a recent publication 
from Scott Lowe’s lab. Utilizing urokinase-type plasminogen activator receptor (uPAR), 
a cell-surface protein that is expressed on senescent cells after palbocicilb and trametininb 




elimination of senescent tumor cells in a lung adenocarcinoma mouse model (Amor et al., 
2020).  
 
The different approaches of utilizing pro-senescence therapy discussed above can 
potentially be implemented for a new, more effective cancer therapy strategies in the 
future. However, like other cancer therapies used in the clinic, pro-senescence therapy 
faces hurdles that need to be overcome. For instance, the response to senolytic drugs 
varies between different senescent cells in different tissues and does not always result in 
an effective clearance of senescent cells. In addition, senescence is required for other 
cellular processes, such as wound healing, which warrant its use with precaution. 
Nevertheless, pro-senescence therapy has a promising potential as a combination cancer 
treatment with immunotherapy in the clinic in the future.     
 
1.3           The MYC oncoprotein 
 
In the final part of this introduction, we will be going through the role of one of the most 
frequently deregulated oncoproteins, MYC, which is in the centre of this thesis. MYC 
was one of the first oncogenes to be identified (Duesberg & Vogt, 1979; Hu, Lai, & Vogt, 
1979; Sheiness & Bishop, 1979). It plays an important role in many cellular processes, 
including cell proliferation, apoptosis, cell growth and metabolism, which place it at the 
heart of many hallmarks that are pivotal in tumorigenesis. As such, understanding MYC 
biology and functions can provide valuable knowledge that can be utilized to improve 
current cancer treatments and develop new and more robust therapeutic approaches to 
combat cancer. During this chapter, I will go in more detail through MYC functions and 
regulation of relevance to this thesis work.  
 
1.3.1 MYC functions 
 
The MYC gene, also known as c-MYC, belongs to the MYC family of proteins that also 
includes N-MYC and L-MYC, with MYC being the most commonly expressed family 
member in different tissues. The MYC gene encodes a transcription factor containing a 
basic region/helix-loop-helix/leucine zipper (bHLHZip) domain and a transactivation 
domain at the C- and N-terminus, respectively. MYC also contains several highly 
conserved regions called MYC boxes (MB0, MBI, II, IIIa, IIIb and IV) located in its 
transactivation domain and central region, and which are essential for MYC’s function in 
transcriptional activation and repression, as well as for its own regulation by other factors 
(Farrell et al., 2014; Kato, Barrett, Villa-Garcia, & Dang, 1990; Murre, McCaw, & 
Baltimore, 1989). The MYC boxes are found in all the MYC family proteins, except for 
the absence of MBIIIb in L-MYC.  
 
MYC regulates the transcription of a variety of genes involved in the cellular processes 
under its control. To achieve this, MYC needs to form heterodimers with the bHLHZip 
protein MAX through the bHLHZip domains of the two proteins. This is crucial for most 
of MYC’s functions (Blackwood & Eisenman 1991) (Mathsyaraja et al., 2019). The 
MYC:MAX heterodimer binds specifically to DNA sequences called E-boxes situated in 
promoter and enhancer regions of target genes. The MYC-type E-boxes are composed of 
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the canonical CACGTG or related sequences (Blackwood & Eisenman, 1991). MYC 
recruits different cofactors to promoters, such as histone acetyl transferase (HAT) 
complexes containing TRAPP or p300/CBP, as well as transcription elongation factor b 
(P-TEFb), and stimulate initiation, pause release and elongation of transcription from its 
target genes (Kress, Sabò, & Amati, 2015; Tu et al., 2015). This ability of the MYC:MAX 
heterodimer and associated co-factors to regulate transcription allows MYC to orchestrate 
multiple processes in the cell, such as cellular proliferation, apoptosis, protein synthesis 
and metabolism. MYC regulates several genes involved in the cell cycle that will be 
described further below. Moreover, MYC activation triggers protein synthesis, through 
the activation of transcription of ribosomal RNA, ribosomal proteins and 5S and tRNAs 
through RNA Pol I, II and III, respectively (Arabi et al., 2005; Gomez-Roman, Grandori, 
Eisenman, & White, 2003; Grandori et al., 2005; Schlosser et al., 2003). MYC also 
contribute to mRNA translation and protein synthesis by the regulation of CAP-
dependent translation initiation factors, such as eukaryotic translation initiation factor 4E 
(eIF4E) (Schmidt, 2004). Further, MYC plays an important role in cellular metabolism 
regulation and energy production, which is frequently deregulated in cancer. For instance, 
it has been shown that MYC activates lactate dehydrogenase A (LDHA) expression, an 
enzyme important in glycolysis, as well as the induction of glutamate metabolism and 
glycolysis by suppressing its negative regulator, miR-23a/b, and deregulating glucose 
transporter 1 (GLUT1) in cancer cells (Gao et al., 2009; Osthus et al., 2000; Shim et al., 
1997). In addition, MYC promotes glycolysis through the induction of pyruvate kinase 
M2 (PKM2) and monocarboxylate transporter 1 (MCT1) (Dang, 2013; Stine, Walton, 
Altman, Hsieh, & Dang, 2015). The high metabolism rate accompanying MYC, in turn 
leads to the production and accumulation of reactive-oxygen species (ROS), which leads 
to DNA damage and genomic instability, an important characteristic often exhibited by 
tumor cells (Egler et al., 2005). Additionally, MYC is known to induce DNA damage via 
replication stress, as a result of elevated replication-fork collapse in hyper-proliferative 
cells (Gorgoulis et al., 2005; Srinivasan, Dominguez-Sola, Wang, Hyrien, & Gautier, 
2013). This can induce apoptosis or senescence, which will be discussed further below. 
 
On the other hand, MYC can also repress the expression of certain genes by cooperating 
with MIZ-1, a zinc finger transcription factor involved in both activation and repression 
of transcription (Peukert et al., 1997; Staller et al., 2001; van Riggelen et al., 2010). The 
MYC:MIZ1 complex represses transcription through the recruitment of DNA methyl 
transferases, which leads to the hypermethylation and the transcriptional inactivation of 
target genes (Licchesi et al., 2010). An important example of this mechanism is the 
silencing of the p21CIP1 gene promoters via MYC:MIZ1 and DNMT3a (Brenner et al., 
2005). In addition, MYC is also suggested to repress transcription indirectly through the 
induction of PTEN, resulting in the activation of EZH2, which modifies chromatin 
structure by histone 3 lysine 27 trimethylation (H3K27me3), and thereby repressing genes 
indirectly (M. Kaur & Cole, 2013). With its wide effect on transcription, MYC’s mode 
of action in transcriptional activation is controversial and an area of discussion. A study 
by Lin and colleagues suggested that MYC acts as a universal amplifier of gene 
transcription, and as such does not regulate specific target genes. This view was opposed 
by work from Amati and colleagues, indicating that MYC drives expression of specific 
sets of target genes, and therefore does not act as a global transcriptional amplifier (C. Y. 




by Walz et al. work, suggesting that MYC regulates distinct classes of target genes, either 
positively or negatively (Walz et al., 2014). However, both sides in this debate seem to 
agree that MYC activation, directly or indirectly has global effects on transcription.  
 
1.3.2 Regulation of MYC expression 
 
MYC expression is controlled on different levels, from transcription to protein turn over, 
and involves many feedback loops and regulators. At the transcription level, MYC 
expression is triggered by several mitogenic signalling pathways driving cellular 
proliferation, such as the RAS, MAPK, WNT/β- catenin and JAK/STAT pathways and 
can also be repressed by anti-growth signalling, such as the TGFβ and interferon 
pathways (C. R. Chen, Kang, Siegel, & Massagué, 2002; He et al., 1998; Kiuchi et al., 
1999; Sears et al., 2000). This regulation often involves super-enhancers found at distant 
upstream or downstream regions from the MYC loci, which act at the promoters from 
long distances (Cao et al., 2017; Schuijers et al., 2018). These signalling pathways and 
regulators ensure timely expression of MYC under different conditions, and the 
deregulation of these pathways, which is often observed in cancer, is one of the 
mechanisms leading to aberrant MYC expression during tumorigenesis. In addition, 
MYC mRNA translation is tightly regulated by the mTOR/eIF4F pathway (Csibi et al., 
2014; Kress et al., 2011; Notari et al., 2006; Wall et al., 2008). mTOR phosphorylates the 
eIF4E-bound 4E-BP, which results in the dissociation eIF4E, which proceeds to interact 
and form a complex with other eIF4 proteins. The eIF4F complex recruits eIF4A to the 
mRNA, unwinding of the secondary structure of its 5’ UTR, which in turn kick start the 
ribosomal translation of the MYC mRNA (Bhat et al., 2015; Roux & Topisirovic, 2018; 
Wiegering et al., 2015; Wolfe et al., 2014).  
 
In addition, MYC is a target for various posttranslational modifications affecting its 
function and stability. Early studies have shown that MYC is subjected to regulation by 
phosphorylation, mainly on its threonine 58 (Thr-58) and serine 62 (Ser-62) residues. 
Phosphorylation of MYC at the Ser-62 residue is for instance mediated by the ERK kinase, 
which was reported to enhance MYC protein stability (Lutterbach & Hann, 1994; Sears 
et al., 2000). The phosphorylation of MYC at Ser-62 plays multiple roles in its regulation 
and function and can also be carried by other kinases, including CDK1, CDK2 and CDK5, 
and serves to activate MYC and its transcriptional activity (Hoang et al., 1995; Hydbring 
et al., 2010; Seo, Kim, Bae, Soh, & Lee, 2008). This phosphorylation also serves as a 
priming event for further MYC phosphorylation by GSK3β, which phosphorylates MYC 
at Thr-58 residue. This ultimately results in MYC protein degradation (Gregory, Qi, & 
Hann, 2003; Lutterbach & Hann, 1994). Thr-58/Ser-62-phosphorylated MYC attracts the 
F-box protein FBXW7 (Welcker et al., 2004), which is the substrate-binding subunit of 
the multi-subunit SCF (SKP1-CULLIN-F-box) E3 ligase complex. The SCFFBXW7 E3 
ligase complex binds and poly-ubiquitylates MYC, thereby targeting it for proteasomal 
degradation (Gregory & Hann, 2000; Salghetti, Kim, & Tansey, 1999; Yada et al., 2004). 
The efficiency of FBXW7-mediated MYC degradation is reported to be dependent on 
prior protein phosphatase 2A (PP2A) activity. PP2A binds Thr-58/Ser-62 phosphorylated 
MYC and dephosphorylates Ser-62 with the help of Peptidyl-prolyl cis-trans isomerase 
NIMA-interacting 1 (PIN1), facilitating subsequent MYC degradation (Yeh et al., 2004). 
Moreover, de-phosphorylation of MYC Ser-62 by PP2A was shown to be inhibited by 
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the protein Cancerous Inhibitor of PP2A (CIP2A), leading to MYC stabilization, which 




Interestingly, RAS induction results in the inactivation of GSK3β via the PI3K/AKT 
pathway, leading to the enhancement of MYC protein stability (Kumar, Marqués, & 
Carrera, 2006). In addition to FBXW7, a number of other E3 ligases also regulate MYC. 
Previous work by our and Bill Tansey’s groups have shown that the F-box protein SKP2 
also interacts with and ubiquitylate MYC, promoting its proteasomal degradation (S. Y. 
Kim, Herbst, Tworkowski, Salghetti, & Tansey, 2003; von der Lehr et al., 2003). 
Interestingly, and in contrast to FBXW7, ubiquitylation and degradation of MYC by 
SKP2 also enhanced MYC-driven transcription. Moreover, it was reported recently that 
the HECT E3 ligase, UBR5 is directly involved in the ubiquitination and degradation of 
the MYC protein (Schukur et al., 2020). Further, work from our group, demonstrated that 
interferon-γ (IFN-γ)-induced p27KIP1 promoted MYC proteasomal degradation through 
direct p27KIP1 binding, engaging an unknown E3 ligase (Bahram et al., 2016). 
Ubiquitylation of MYC by E3 ligases is not always resulting in MYC degradation. For 
instance, poly-ubiquitylation of MYC by HUWE1/HECTH9 or FBXO28 leads to the 
recruitment of acetylation complexes such as TRAP and p300/CBP, enhancing MYC’s 
transcription activation function (McMahon, Van Buskirk, Dugan, Copeland, & Cole, 
1998; K. Zhang, Faiola, & Martinez, 2005). In addition, E3 ligase β-TRCP has been 
Figure 6: Regulation and function of MYC. The MYC proto-oncogene is regulated by major growth-
regulatory and oncogenic signalling pathways. Overview of the different cellular processes and targets 
regulated by MYC. Adopted from. Kress TR, Sabò A, Amati B. et al., MYC: connecting selective 




shown to stabilize the MYC protein by inducing poly-ubiquitination via the UbcH5 
ubiquitin-conjugating enzyme, antagonizing Fbw7-mediated ubiquitination (Popov, 
Schülein, Jaenicke, & Eilers, 2010). 
 
1.3.3 MYC in cancer 
 
The MYC protein is deregulated in over half of human cancers and is often associated 
with poor prognosis (Stine et al., 2015). In fact, MYC is the most frequently amplified 
oncogene in human cancer (Beroukhim et al., 2010), ranging from over 30% of ovarian 
cancer, 21% of breast cancer and 14% of pancreatic adenocarcinomas, among others 
(Bailey et al., 2016; C. G. A. R. Network, 2011). Amplification of the other members of 
the MYC family, such as MYCN and MYCL is also observed in human cancers, such as 
neuroblastoma and small cell lung carcinoma (C. G. A. Network, 2012; Pugh et al., 2013). 
Gene amplification is not the only form of MYC aberration observed in cancer. 
Chromosomal translocation leading to MYC deregulation is observed in Burkitt’s 
lymphoma and multiple myeloma, in which the MYC locus is placed in the vicinity of 
the highly active immunoglobulin enhancers (Finver et al., 1988; Jiménez et al., 2017). 
In addition to the chromosomal aberrations mentioned above, MYC deregulation in 
cancer cells can also be caused by deregulated expression due to genetic or epigenetic 
aberrations affecting super-enhancers controlling the MYC loci observed in T cell 
leukaemia’s for instance, or indirectly through the constitutive activation of pathways 
upstream of MYC, such as the MAPK and WNT pathways observed in different tumor 
types (Hnisz et al., 2013; Myant & Sansom, 2011; Romeo et al., 2015; Sears, Leone, 
DeGregori, & Nevins, 1999; J. Zhu, Blenis, & Yuan, 2008)  (Bellahcène, Castronovo, 
Ogbureke, Fisher, & Fedarko, 2008; Chan et al., 2010). Other mechanism of MYC de-
regulation in cancer is through the stabilization of MYC protein level. An example of this 
is the loss of FBXW7, a regulator of MYC protein turnover, which results in the 
stabilization and subsequent deregulation of the MYC protein (Davis, Welcker, & 
Clurman, 2014). GSK3β inactivation, by the RAS/PI3K/AKT pathway for instance, is 
another mechanism that is frequently observed in cancer cells to deregulate the MYC 
protein, which also results in blocking GSK3β phosphorylation of MYC at Thr-58 and 
preventing MYC degradation (Manning & Toker, 2017; Sears et al., 2000). Another 
mechanism observed in Burkitt’s lymphoma is mutations in MYC Thr58, which plays an 
important role in regulating MYC protein stability, resulting in a substantial reduction of 
proteasome-mediated degradation and ubiquitination, leading to MYC deregulation 
(Bahram, von der Lehr, Cetinkaya, & Larsson, 2000; Salghetti et al., 1999). Moreover, 
the overexpression of CIP2A in different types of cancers, which inhibit Ser-62 
phosphorylation by PP2A and protect MYC from proteasomal degradation (Khanna, 
Pimanda, & Westermarck, 2013).The dependency on MYC for sustained tumor growth 
has been highlighted in many studies. For instance, in vivo studies in mice elegantly 
demonstrated tumor regression upon MYC inactivation for many types of tumors, such 
as T cell lymphoma, acute myeloid leukemia and pancreatic cancer mouse models 
(Arvanitis & Felsher, 2005; Felsher & Bishop, 1999; Jonkers & Berns, 2004; Pelengaris, 
Khan, & Evan, 2002). These studies utilized the conditional tetracycline-induced system 
(Tet-on/Tet-off) or the conditional tamoxifen-induced system to activate and deactivate 
MYC expression at will in vivo. In the tetracycline induced system, the expression of the 
gene of interest, which is placed under the tetracycline response element (TRE) promoter, 
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is either activated (on) or deactivated (off) by the tetracycline transactivator protein (tTA). 
The tTA protein activity requires tetracycline, or its derivatives such as doxycycline, to 
activate/deactivate the expression of the gene of interest. In the tamoxifen-induced system, 
the protein of interest is fused to a modified human-estrogen ligand-binding domain (ER), 
where the activity of the ER-fused protein is triggered by 4-hydroxytamoxifen/tamoxifen. 
In these studies, turning off MYC expression in established tumors, by the withdrawal of 
doxycycline or tamoxifen, induced apoptosis and tumor regression, highlighting tumor 
dependency on MYC. This observation gave rise to the theory of ‘oncogene addiction’, 
where cancer cells become highly dependent on the expression of certain oncogenes for 
their survival. Another demonstration of MYC’s importance in tumor progression was 
provided by a work by Gerald Evan, Laura Soucek and colleagues. In their studies, an 
inducible dominant negative form of MYC, termed Omomyc, was able to block tumor 
formation and induce tumor regression in a KRAS-driven lung tumor model, which was 
only overcome by silencing of Omomyc selected for in a small subset of tumors cells  
(Soucek et al., 2008; Soucek et al., 2013). The Omomyc approach was further evaluated 
in many different cancer models, including invasive astrocytoma, WNT-driven breast 
cancer model, patient-derived glioblastoma xenografts and PDAC mouse model. The 
results from these studies demonstrated that the tumors were dependent on (or “addicted 
to”) MYC to maintain tumor proliferation, progression and for remodelling of the micro-
environment (Alimova et al., 2019; Annibali et al., 2014; Beaulieu et al., 2019; Galardi 
et al., 2016). Similarly, a study from Sansom et al. using a model of adenomatous 
Figure 7: Role of MYC in cancer development. MYC is involved in many different processes 




polyposis coli (APC)-deficient colorectal cancers, which is characterised with 
deregulated WNT/ β-catenin pathway, demonstrated that WNT-driven MYC expression 
is required for the molecular and pathological phenotypes associated with tumor 
progression (Sansom et al., 2007).  
 
MYC is clearly essential for many cellular processes during cancer development. 
Different studies provide evidence that MYC expression is required for a proper execution 
of angiogenesis during tumorigenesis through regulation of VEGF, HIF-1α and other 
angiogenic factors (Baudino et al., 2002; C. W. Chen, Yeh, Shiau, Chiang, & Lu, 2013). 
MYC has also been proposed to play a role epithelial-to-mesenchymal transition (EMT). 
This process is often driven by TGF-β and its downstream transcription factor SNAIL. 
Studies have demonstrated that MYC can activate SNAIL through regulating several 
micro-RNA clusters targeting SNAIL (A. P. Smith et al., 2009). Additionally, MYC also 
seems to play a role in cell invasion, migration, and metastasis, although this is 
controversial. A pro-metastatic role for MYC was proposed based on its regulation of 
proteins required for cytoskeleton regulation and remodelling, such as OPN, LGALS1 
and RHOA, which also plays a role in migration, cell invasion and EMT (Chan et al., 
2010; C. Martinez, Churchman, Freeman, & Ilyas, 2010; T. Wang et al., 2019; Yan et al., 
2009). On the other hand, work from Bishop lab and others rather suggested that MYC 
does not induce invasion and metastasis using a primary keratinocytes model, as well as 
breast cancer models, and instead downregulated the expression of α and β integrins 
involved in invasion and metastasis (Gebhardt et al., 2006; H. Liu et al., 2012; Welm, 
Kim, Welm, & Bishop, 2005). Another report has also suggested that MYC expression 
dramatically blocked tumor invasion and cell migration in. human lung adenocarcinoma 
cells and drosophila models (Ma et al., 2017). Further studies are required to determine 
whether MYC promotes invasion and metastasis or not, and whether this might be context 
dependent. Taken together, the studies above emphasize the important role of MYC in 
different aspects of the tumorigenesis, and during the rest of this chapter, I will focus on 
certain characteristics of MYC that are particularly relevant to this thesis work. 
 
1.3.4 MYC and the cell cycle 
 
One of the prominent roles of MYC is its effect in promoting cell cycle and proliferation. 
Following mitogenic signalling, MYC levels increase dramatically and aid in facilitating 
the progression during the different stages of the cell cycle by regulating expression of 
different proteins involved in this process. For instance, it has been shown that MYC 
induces the expression of cyclin D2 and CDK4, which together form a complex that 
phosphorylates and inactivates RB during late G1 phase of the cell cycle (Hermeking et 
al., 2000). Additionally, MYC contributes to upregulation of cyclin E1 and cyclin E3 
expression, required for CDK2 function during cell cycle progression (Bouchard et al., 
1999; Steiner et al., 1995) (Steiner, 1995). MYC’s effect on cell cycle extends to the 
promotion of G2/M phase transition through the induction of cyclin B expression, and 
subsequently enhancing the formation of cyclin B/CDK1 complexes required for M phase 
entry (Yin et al., 2001). Aside from induction of CDKs and cyclins, MYC also promotes 
the cell cycle by regulating CKIs involved in blocking cell cycle progression. For example, 
MYC causes sequestering of p27KIP1 via induction of CDK4/6-cyclin D complexes, which 
bind p27KIP1, thereby freeing CDK2-cyclin E from inhibition by p27KIP1 and resulting in 
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the hyperphosphorylation of RB and the transition to S phase (Pérez-Roger, Solomon, 
Sewing, & Land, 1997). Furthermore, MYC suppresses p27KIP1 levels through different 
mechanisms. At the mRNA level, MYC represses p27KIP1 expression either directly by 
inhibiting Forkhead box O proteins FOXO3a from activating the p27 promoter or through 
miRNA-222 and miRNA-221 targeting p27 mRNA (Chandramohan et al., 2008; J. W. 
Kim, Mori, & Nevins, 2010; W. Yang et al., 2001). Additionally, MYC enhances 
expression of components of the SCFSKP2 E3 ubiquitin ligase complex, which recognize 
p27KIP1 after phosphorylation by the CDK2-cyclin E complex, leading to 
p27KIP1ubiquitylation and proteasome-mediated destruction (Bretones et al., 2011; 
Montagnoli et al., 1999). The expression of the CDK inhibitors p15INK4b and p21CIP1 are 
also repressed by MYC together with MIZ-1 (Staller et al., 2001; Wu et al., 2003). At 
high MYC levels, MYC binds MIZ1 and recruits the DNA methyltransferase DNMT3a 
to p15INK4b and p21CIP1 gene promoters, leading to the subsequent methylation and 
inactivation these genes (Brenner et al., 2005; Staller et al., 2001). p15INK4b is known to 
bind to and inhibit CDK4/6 following its induction by the TGF-β pathway, thereby 
blocking the cell cycle progression and inducing cell cycle arrest (Sherr & Roberts, 1995). 
p21CIP1 blocks cell cycle progression by binding to and inhibiting CDK2-cyclin E and 
CDK2-cyclin A, which are active during late G1 and S phases of the cell cycle (Gartel, 
2005). p21CIP1 is also reported to regulate DNA synthesis and DNA damage repair in 
association with proliferating cell nuclear antigen (PCNA) (Waga, Hannon, Beach, & 
Stillman, 1994; Xiong, Zhang, & Beach, 1992). MYC has also been reported to play a 
role in DNA replication. It induces the expression of proteins important for replication, 
such as Cell Division Cycle 6 (CDC6), origin complex recognition complex (OCR) and 
minichromosomal maintenance proteins (MCMs), proteins required for replication 
initiation and elongation during DNA replication (Fernandez et al., 2003; Zeller et al., 
2006). In addition, MYC promotes nucleotide production, thereby further contributing to 
replication and DNA synthesis (Mannava et al., 2008). Furthermore, MYC also triggers 
expression of components of the APC/C protein complex, an important factor regulating 
the destruction of securin and cyclin B1, which is a perquisite for induction of anaphase 
(Primorac & Musacchio, 2013). Moreover, MYC also plays a role in maintaining 
telomeres through the induction of hEST2 expression and upregulating expression of the 
telomerase subunit hTERT, which is limiting in adult cells, and one of the key features in 
tumor development (J. Wang, Xie, Allan, Beach, & Hannon, 1998). Finally, MYC is 
involved in senescence regulation, which we will be revisited in the next section. These 
many different contributions of MYC to cell cycle progression place it at the heart of 
cancer development.   
 
1.3.5 MYC in apoptosis and senescence 
 
In addition to its well-documented role in promoting cellular proliferation and growth, 
high MYC expression triggers apoptosis both through the intrinsic and extrinsic apoptotic 
pathways and affect several proteins regulating this process (Askew, Ashmun, Simmons, 
& Cleveland, 1991; Evan et al., 1992; Klefstrom, Verschuren, & Evan, 2002). MYC 
activation leads to induction of p19ARF, which inhibits MDM2, leading to the stabilization 
of p53. p53 induces pro-apoptotic modulators, such as NOXA and PUMA, and trigger 
apoptosis (Nakano & Vousden, 2001; Villunger et al., 2003; Zindy et al., 1998). In 




mitochondrial membrane, and initiates apoptosis via the intrinsic pathway (Soucie et al., 
2001). Oncogenic MYC can also prime the mitochondria for TRAIL-induced caspase-8 
signals through a mechanism involving activation of BAK, which leads to activation of 
BAX and ultimately apoptosis (Nieminen, Partanen, Hau, & Klefstrom, 2007). Another 
mechanism in which MYC triggers apoptosis in a p53-independent manner is via the 
induction of BIM, a BH3-only pro-apoptotic factor (Egle, Harris, Bouillet, & Cory, 2004). 
BIM induction render the cell susceptible to FAS and TNF-α mediated cell death. In 
addition to the induction of pro-apoptotic factors, MYC has been reported to suppress 
anti-apoptotic factors, such as BCL-2 and BCL-XL, which also contributes to its 
apoptotic effect (Eischen, Woo, Roussel, & Cleveland, 2001; Galardi et al., 2016). It is 
worth noting that the ability of MYC to induce apoptosis is dose dependent.  High 
expression levels of MYC strongly induces apoptosis, whereas moderate MYC levels was 
reported to enhance the rate of cell proliferation while exhibiting low apoptotic index 
(Murphy et al., 2008). Nevertheless, tumor cells can circumvent  the effect of high MYC 
expression by upregulating anti-apoptotic factors or through other mechanisms of 
apoptosis suppression (Schmitt & Lowe, 2001). For instance, overexpression of BCL-2 
and p53 mutations/deletions are common during MYC-driven cancer development, which 
provide cancer cells with an escape route and thereby allow MYC overexpression and 
proliferation without triggering apoptosis (Meyer & Penn, 2008). 
 
MYC has also been linked to cellular senescence. The role of MYC in senescence is 
complex and may depend on the cell type and the underlying genetic makeup of the 
tumors. MYC was shown to suppress BRAFV600E or NRAS161R-induced senescence in 
human melanoma cells, as MYC overexpression in these cells blocked senescence 
induction (Zhuang et al., 2008). Similarly, overexpressing MYC in rat embryonic 
fibroblasts (REFs) abrogated HRAS-induced senescence, which was countered by p27kip1 
overexpression (Hydbring et al., 2010). The ability of MYC to counter RAS-induced 
senescence was shown to be dependent on CDK2, via MYC phosphorylation by CDK2 
on Ser-62. Additionally, importance of MYC in suppressing oncogenic-induced 
senescence was demonstrated in vivo using mouse lung models driven by BRAFV600E (S. 
Campaner et al., 2010; Juan, Muraguchi, Iezza, Sears, & McMahon, 2014; Tabor, Bocci, 
Alikhani, Kuiper, & Larsson, 2014). MYC suppression of senescence induced by RAS or 
BRAFV600E in cultured cells and in vivo was linked to suppression of p21CIP1 and p16INK4a 
mediated by MYC (Hydbring & Larsson, 2010; Tabor et al., 2014). However, MYC has 
also been reported to induce senescence under certain conditions. For instance, Werner 
syndrome gene (WRN)-deficient fibroblasts underwent senescence following MYC 
overexpression in a similar way as CDK2-deficient cells (S. Campaner et al., 2010; 
Grandori et al., 2003). Conversely, MYC expression was unable to suppress RAS-
induced senescence in normal human fibroblasts, regardless of p53 status (Zhang et al., 
2018). These studies suggest that the role of MYC in regulating senescence is dependent 
on other factors that dictate the response to MYC overexpression with respect to 
senescence induction or suppression.     
 
1.3.6   MYC and its role in tumor immunity 
 
In recent years, a new role of MYC in tumor development is emerging. Aside from its 
promotion of cellular proliferation and growth discussed above, MYC has been 
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implicated in facilitating cancer cell evasion of immune surveillance.  Early studies by 
Rakhra et al. in Dean Felsher’s lab showed that MYC inactivation resulted in enhanced 
recruitment of CD4 T cells into the tumor microenvironment and tumor regression in a 
MYC-driven T cell acute lymphoblastic lymphoma (ALL) mouse model (Rakhra et al., 
2010). In a follow up of the Rakhra study using a MYC-regulated Tet-off system in 
transgenic mouse model of hepatocellular carcinoma, Felsher’s lab showed that MYC 
inactivation led to the downregulation of expression of two important immune modulators, 
PD-L1 and CD47, in the tumor cells (Casey et al., 2016). Both of these receptors are 
involved in cancer cell immune evasion mechanisms, as PD-L1 block CD8 cytotoxic T 
cell activation while CD47 protect cells from macrophage phagocytosis. In the same study, 
knockdown of MYC using shRNA or using the BRD4 inhibitor JQ resulted in similar 
downregulation of PD-L1 and CD47 expression in different human cancer lines. In 
addition, chromatin immunoprecipitation sequencing (ChIP-seq) analysis revealed that 
MYC bound directly to PD-L1 and CD47 promoters when highly expressed, indicating a 
direct regulation of these genes by MYC. Further, Atsaves et al showed that MYC 
regulate PD-L1 expression transcriptionally following JAK1/STAT3 activation upstream 
of MYC in ALK-driven anaplastic large-cell lymphoma cells (Atsaves et al., 2017). A 
role of MYC in the regulation of PD-L1 was suggested also in several other in vitro and 
in vivo studies, including reports from patient-derived xenografts, lung cancer, 
lymphomas as well as neuroblastoma driven by MYC or MYCN (E. Y. Kim, Kim, Kim, 
& Chang, 2017; Melaiu et al., 2017). Another study by the Klefström lab demonstrated 
that pharmacological reactivation of MYC-dependent apoptosis by AMPK and BCL-
2/BCL-XL inhibitor treatment, followed by PD-L1 depletion induced immune infiltration 
to the tumor tissue and enhanced survival in a MYC-driven mammary breast cancer 
model, showing a synthetic-lethal MYC strategy involving the immune compartment 
(Haikala et al., 2019). Another study by Topper et al., also implicated MYC in 
immunosuppression and the exhaustion of CD8 T cells in a KRASG12D lung 
adenocarcinoma model (Topper et al., 2017). Their work demonstrated that the dual 
inhibition of DNMTs and HDACs, by aza-cytidine and ITF-2357 respectively, resulted 
in downregulation of MYC, induction of both CCL5 and IFN-α/β signalling, culminating 
in the activation of T cell response. These studies highlight a new non-cell autonomous 
role for MYC during tumor development, in addition to its control of tumor proliferation 
and survival through intrinsic mechanisms. 
 
The mechanisms by which MYC exerts its effect on the immune system are still not fully 
deciphered. To gain more insight on MYC’s immunomodulatory role in cancer, Kortlever 
et al. evaluated changes in the tumor microenvironment in relation to MYC status using 
a KRASG12D/MYC-driven lung adenocarcinoma mouse model. MYC inactivation was 
shown to coincide with an influx of NK, B and T cells into the tumor area, as well as with 
rapid regression of tumor mass (Kortlever et al., 2017). These changes were attributed to 
CCL9 and IL-23 overexpression by the tumor cells, as the depletion of these 
immunomodulators negated the immunosuppressive ability of MYC in this model. 
However, the tumor cells did not show upregulation in PD-L1 in response to MYC 
activation in this case, instead increased PD-L1 expression was observed in the 
macrophage cell population. This observation contradicts previous findings by Casey et 
al., suggesting that MYC’s modulation of the immune system differs depending on the 




contributed to this discrepancy, is the different levels of MYC in the two systems, as 
Kortlever et al. used lower expression levels of MYC compared to the study by Casey et 
al. A recent study by Sodir et al., where the effects of MYC on the tumor stromal 
compartment and tumor development was investigated using a KRASG12D/MYC-driven 
pancreatic ductal adenocarcinoma mouse model, the authors showed that MYC activity 
promoted immune evasion (Sodir et al., 2020). However, the study showed clear 
differences in the immune cell’s response to MYC activity in tumor cells between the 
pancreas and the lung tumors. For instance, MYC activation in the pancreas tumors led 
to the influx of B cells into the tumor periphery, which was opposite to what was observed 
in the lung adenocarcinoma model. This effect was attributed to the presence vs. lack of 
IL-23 signalling in the PDACs and lung adenocarcinomas, respectively (Kortlever et al., 
2017; Sodir et al., 2020). Furthermore, the PDACs showed elevated expression of PD-L1 
on the surface of the tumor epithelium, in contrast to the lung adenocarcinoma model 
where the induction of PD-L1 expression was detected on the resident macrophages. In 
addition, the recruitment of suppressor Ly-6B+ neutrophils and G-MDSC reported in 
PDAC model following MYC activation was not observed in the lung tumor model.  
MYC inactivation in the PDACs lead to a fast tumor regression, which was accredited to 
the activity of infiltrating NK cells. Using another PDAC model, Daniel Murphy’s lab 
reported similar findings and provided some mechanistic insight on how MYC elicits its 
immune suppressive function. ChIP analysis in human PDAC cells suggested that MYC 
and MIZ-1 together bind to STAT1, STAT2, IRF5, and IRF7 promoters, thereby 
suppressing these genes (Muthalagu et al., 2020). Further, PDACs carrying a floxed 
version of MIZ1, which is unable to bind MYC, showed a significant enhancement in 
overall survival. The study also showed that depletion of CXCL13, which is secreted by 
a subset of macrophages, depletion of type I interferon receptor 1 (IFNAR-1) or of NK 
cells abrogated MYC’s suppression of B- and NK cell infiltration into the tumor area. 
Additionally, a recent study by Swaminathan et al. showed that MYC block NK 
maturation via the repression of STAT1/2 and type I IFNs, leading to the impairment of 
NK cells maturation and function in a model MYC-driven T cell lymphoma 
(Swaminathan et al., 2020). Moreover, they demonstrated that the administration of IFN-
α rescued NK cell maturation and triggered their activation. The different studies 
discussed above demonstrate a clear role of MYC in immune suppression and evasion of 
killing by NK cells, resulting in tumor progression. Interestingly, these studies did not 
implicate T cells in the anti-tumor immune response following MYC inactivation, which 
one would have expected considering the PD-L1 regulation observed in some of these 
studies. Nevertheless, these studies clearly suggest that MYC participates in suppressing 
the immune system during cancer progression. However, further research is needed to 
deepen our standing of the mechanisms underlying this phenomenon and to clarify the 
role of different immune cells and immunomodulatory molecules involved in order to 
improve current cancer therapies. 
 
1.3.7    MYC inhibition and cancer 
 
Given the important role of MYC during the development of so many human cancers, it 
is considered an attractive target for cancer therapy. Several of the studies using different 
mouse tumor models mentioned above have demonstrated that MYC inactivation in 
established tumors resulted in tumor regression or hampering further tumor development. 
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The reason for this might be that MYC is involved in so many different processes crucial 
for cancer development and maintenance leading to “MYC addiction”, further raising its 
value as promising target. Through the past two decades, many attempts have been made 
to develop inhibitors that can target MYC. This proved to be challenging, as certain 
characteristics of the MYC protein render it hard to target. In particular, the lack of 
enzymatic activity, the intrinsically disordered protein structure without defined ligand-
binding sites makes it difficult for the design of highly specific and effective inhibitors. 
Nevertheless, many efforts are ongoing to develop therapeutics that can target MYC in 
cancer cells. These have been focused on different aspects of MYC regulation and 
function, ranging from blocking its interaction with important partner proteins, interfering 
with transcription or translation of MYC mRNA, to modulating its protein turnover. 
These different approaches have shown varying degrees of success as well as pitfalls, that 
can hopefully be used to refine the strategies to effectively target MYC in cancer in the 
future.  
 
One of the approaches that have been investigated is the inhibition of MYC transcription 
by blocking different transcription regulators and epigenetic modulators, for instance 
BET proteins, histone deacetylases, histone methyltransferases and DNA 
methyltransferases that are known to participate in regulation of MYC expression. An 
example of this class of inhibitors are BET inhibitors and HDAC inhibitors. The BET 
family of proteins, such as BRD4, promote transcription and RNA pol II release via the 
recruitment of transcription elongation factor b (P-TEFb) to promoters to induce 
transcriptional elongation, particularly of genes involved in cell growth, including MYC 
(Z. Yang, He, & Zhou, 2008). Indeed, some cancer studies using the BET inhibitor JQ1 
did show a reduction in the expression levels of MYC, leading to inhibition of tumor cell 
proliferation and tumor regression in vitro and in vivo (Bandopadhayay et al., 2014; da 
Motta et al., 2017; Delmore et al., 2011). However, JQ1 and other BET inhibitors did not 
have an effect on MYC expression in all cell types or tumor models, and its efficacy in 
clinical trials of refractory lymphoma, multiple myeloma, diffuse large B cell lymphoma 
among others were not overwhelming, as the treatment had limited effect and the patients 
showed tumor relapse (Bhadury et al., 2014; Doroshow, Eder, & LoRusso, 2017). This 
seemed to be caused by significant alterations in signalling pathways due to cellular 
adaptation to the inhibition of BRD4, resulting in resistance to treatment (Kurimchak et 
al., 2016). Despite these shortcomings, new studies reported an increased sensitivity of 
these resistant cells to kinase inhibitors, as the combination treatment of JQ1 and PI3K 
inhibitors induced cell death in pancreatic carcinoma and MYCN-amplified 
neuroblastoma cell lines (Andrews et al., 2017). These observations open the possibility 
to the use of combination treatment against MYC and other cooperating oncogenic drivers 
as a promising new treatment. Moreover, other BET inhibitors, such as AZD5153, ZEN-
3694 and GSK525762 have shown encouraging results in MYC-driven tumor models and 
currently clinical trials are ongoing to evaluate its overall efficacy in prostate cancer and 
leukemia patients (Baumgart & Haendler, 2017; B. Li & Simon, 2013; Rhyasen et al., 
2016). Another approach to inhibit MYC transcription aims at targeting DNA structures 
called G-quadruplexes, which are involved in gene silencing. In this strategy, the G-
quadruplex structures residing in the nuclease hypersensitive element (NHE) III region 
of the MYC promoter are stabilized using small molecules, such as GQC-05 (Hurley, 




shown significant reduction in MYC mRNA and protein expression, and downregulation 
of the MYC gene signature following treatment with these small molecule G-quadruplex 
stabilizers. Treatment with these molecules also led to cell cytotoxicity in non-Hodgkins 
lymphoma, renal cell carcinoma and Burkitt’s lymphoma cells (Bouvard et al., 2017; 
Brown, Danford, Gokhale, Hurley, & Brooks, 2011; Das, Panda, Saha, & Dash, 2018). 
While this approach still requires further evaluation in vivo and in clinical trials to 
determine its overall potential and side effects, it nevertheless provides a new promising 
tool to combat MYC in cancer. 
 
Another strategy to inhibit MYC centres around the posttranslational regulation and 
protein turnover of MYC. As discussed earlier, MYC undergoes many posttranslational 
modifications that regulate MYC protein stability and activity. One of the approaches in 
this strategy focuses on proteins involved in Ser-62 phosphorylation. Protein phosphatase 
2A (PP2A), a serine/threonine phosphatase, plays an important role in regulating MYC 
function and protein stability by dephosphorylating MYC at Ser-62 (Arnold & Sears, 
Figure 8: MYC regulatory pathways and therapeutic points of intervention. Different strategies to 
inhibit MYC and its functions. Adopted from Allen-Petersen, B. L. and Sears, R. C. et al., Mission 
Possible: Advances in MYC Therapeutic Targeting in Cancer. BioDrugs. 2019; 33: 539-553. 
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2008). Recently, small-molecule activators of PP2A (SMAPs), have shown promising 
results in reactivating PP2A and reducing MYC levels, among other oncogenes, in lung 
cancer cells (Kauko et al., 2018; Sangodkar et al., 2017). Additionally, work from Rosalie 
Sears’ lab recently showed that the combination of DT1154, a SAMP, and INK128, an 
ATP-competitive mTORC1/2 inhibitor, synergistically reduced MYC levels and 
triggered apoptosis in breast cancer cells and in a PDAC xenograft mouse model (Allen-
Petersen et al., 2019). The PP2A activation strategy to inhibit MYC prompts further 
investigation of its potential in pre-clinical and clinical studies. Another approach 
utilizing PP2A is through interfering with its cellular inhibitors, such as inhibitor-2 of 
protein phosphatase-2A (SET). For instance, studies using OP449, a molecule 
sequestering SET, led to the activation PP2A, decreased Ser-62 phosphorylation and 
blocked tumor growth in pancreatic and breast cancer cells (Farrell et al., 2014; 
Janghorban et al., 2014). Similarly, SET sequestering by OP449 induced a cytotoxic 
response in ABL inhibitor-resistant acute myeloid leukaemia (AML) and chronic myeloid 
leukaemia (CML) cells, albeit the study did not investigate the effect on Ser-62 MYC 
levels (Agarwal et al., 2014). Additionally, targeting CDK2 to abrogate Ser-62 
phosphorylation has been shown to trigger cellular senescence in cells and in MYC-
driven AML and medulloblastoma mouse models, which we will discuss further in papers 
I and II (Bazzar et al., 2021; Hydbring et al., 2010). In contrast CDK2 depletion resulted 
in apoptosis induction in neuroblastoma cell lines, suggesting  that different tumor types 
respond differently to CDK2 inhibition (Bolin et al., 2018) (Molenaar et al., 2009). Along 
the lines of utilizing CDK inhibitors to block MYC activity, the dual inhibition of CDK9 
and MYC, via LDC000067 and BET inhibitor (BI 894999) respectively, inhibited tumor 
proliferation and induced apoptosis in models of AML and hepatocellular carcinoma 
(Gerlach et al., 2018; Hashiguchi et al., 2019; C. H. Huang et al., 2014). Similarly, 
blocking of CDK7, which is part of the transcription factor II (TFIIH) complex involved 
in RNA pol II phosphorylation and transcription initiation, led to the loss of the MYC 
transcription signature, reduction of tumor cell proliferation in MYC-amplified ovarian 
cancer cell lines and MYCN-amplified cancer cells and tumor regression in patient-
derived xenograft tumor models (Chipumuro et al., 2014; McDermott et al., 2020; Zeng 
et al., 2018). Moreover, targeting of the ubiquitination/deubiquitination machinery 
involved in MYC regulation, such as FBXW7, SKP2, PIN1, HUWE1 and de-
ubiquitinating enzymes (DUBs) can potentially be a useful tool to block MYC by 
reducing its activity or stability (E. Campaner et al., 2017; Peter et al., 2014; Tavana et 
al., 2016). For instance, Aurora kinase A (AURKA), which is involved in centrosome 
maturation and separation, binds MYCN and prevent its ubiquitination by FBXW7 (Otto 
et al., 2009). Studies from Brockmann et al. demonstrated that pharmacological inhibition 
of AURKA induced FBXW7-dependent MYCN degradation, leading to reduction in 
tumor proliferation and prolongation of survival in MYCN-amplified neuroblastoma 
xenografts and in the TH-MYCN neuroblastoma mouse model (Brockmann et al., 2013; 
Gustafson et al., 2014) 
 
Finally, efforts have been made towards blocking MYC function by inhibiting its 
dimerization with its partner protein, MAX. As discussed earlier, MAX is crucial for 
MYC binding to E-box sequences and transcriptional activity and blocking MYC:MAX 
interaction can therefore abrogate MYC’s activity in cells. First generation MYC-MAX 




viability but suffered from off target effects and low in vitro and in vivo potency, with a 
high half-maximal inhibitory concentration (IC50) values ranging from 20 to 40 μM 
(Carabet, Rennie, & Cherkasov, 2018; Fletcher & Prochownik, 2015; McKeown & 
Bradner, 2014). Several efforts have been made to improve the specificity and efficacy 
of MYC:MAX inhibitors and recently some reports are showing more promising results. 
Our lab has identified two MYC:MAX inhibitors, MYCMI-6 and MYCMI-7, which 
displayed significantly lower IC50s and selectivity in blocking MYC:MAX dimerization 
and strong anti-tumor effects in vitro and in vivo, which I will discuss in paper III and IV 
(Castell et al., 2018). In addition, two other small molecule MYC:MAX inhibitors, named 
MYCi361 and MYCi975, that increased proteasome-mediated MYC degradation and 
showed strong downregulation in the MYC transcriptional program in vitro were reported 
in a recent study by Han et al. (Han et al., 2019). Furthermore, treatment with these 
compounds in allograft and xenograft tumor mouse models showed a significant 
reduction in tumor growth, upregulation of PD-L1 on tumor cells, increased immune 
infiltration and sensitization of tumors to anti-cancer immunity following PD-L1 
depletion. Recently, a purified small Omomyc peptide that exhibit strong affinity to both 
MYC and MAX, and thereby block the dimerization between endogenous MYC and 
MAX, surprisingly exhibited good efficacy in penetrating the cell membrane and was 
capable of disrupting MYC-dependent transcription (Beaulieu et al., 2019). The strong 
anti-MYC capability of the Omomyc peptide was observed both in human cancer cell 
lines and in lung adenocarcinoma mouse models. Finally, an alternative approach using 
the small molecule KI-MS2-008, which stabilizes MAX:MAX homodimers, resulted in 
MYC degradation and downregulation of MYC target genes in cells, and exhibited 
inhibitory effects on tumor growth in vivo (Struntz et al., 2019). These different strategies 
demonstrate that MYC can be targeted by different means and provide encouraging 


























The overall aim of this thesis was to increase the knowledge about MYC regulation and 
function and to evaluate different approaches of targeting MYC and its partners in cancer 
cells in order to find new therapeutic strategies to block MYC-driven tumor development 
in the future. In the first part of the thesis, I aim to elucidate the role of CDK2 in MYC-
mediated senescence suppression and immune evasion during tumor development and to 
evaluate the potential of CDK2 depletion/inhibition as therapeutic principle to reverse 
these processes in vivo. In the second part of the thesis, I am to identify and characterize 
new small molecule MYC:MAX interaction inhibitors and evaluate the potency and 
selectivity with respect to blocking MYC-dependent tumor cell growth in cell cultures 
and in vivo.  
 
In brief, the specific aims of each of the papers are the following: 
 
Paper I: To investigate the efficacy of CDK2 pharmacological inhibition in inducing 
senescence and attenuating MYC-driven tumor development in vivo using a MYC/BCL-
XL-driven acute myeloblastic leukemia (AML) mouse model. 
 
Paper II: To unravel the role of CDK2 in BRAFV600E/MycER-driven lung tumor 
development in vivo and its impact on MYC-mediated senescence regulation and 
immunosuppression using a conditional immunocompetent mouse lung tumor model.  
 
Paper III and paper IV: To characterize the small molecule MYC:MAX inhibitors 
MYCMI-6 and MYCMI-7, and to evaluate their efficacy in inhibiting MYC-driven tumor 
growth in cell cultures and using mouse tumor models in vivo representing AML, breast 























3 Results and Discussion 
 
3.1   CDK2 depletion/inhibition induces senescence and immune cell infiltration, 
reduces tumor burden and prolongs survival in MYC-driven mouse tumor models 
(Papers I and II) 
 
MYC is one the most frequently deregulated oncogenes in human cancer and plays a major 
role in tumor development. Overexpression of MYC is known to induce apoptosis, which 
acts as a barrier against tumor development, but tumor progression is often accompanied 
by loss of genes involved in apoptosis induction, such as p53 and PTEN or deregulation of 
proteins blocking apoptosis such as PI3K, RAS and BCL-2 or BCL-XL. In addition to 
induction of apoptosis, MYC has been shown to suppress oncogene-induced senescence, a 
second important barrier against tumor development. Our previous work in REFs 
demonstrated that inhibition of oncogenic RAS- or BRAF-induced senescence by MYC is 
dependent on phosphorylation of MYC at Ser-62 by CDK2 (Hydbring et al., 2010). This 
observation potentially provides a new strategy to abrogate MYC function in cancer cells. 
To evaluate this strategy in vivo, we examined the effect of CDK2 depletion/inhibition on 
MYC-driven tumor development using two different mouse tumor models, MYC-driven 




In paper I, we utilized a MYC/BCL-XL-driven mouse myeloblastic leukemia model, 
described in (Högstrand et al., 2012), to evaluate the efficacy of CDK2 pharmacological 
inhibition in blocking tumor development and inducing senescence in vivo. To inhibit 
CDK2, we utilized the selective CDK2 inhibitors CVT313 and CVT2584 used in our 
previous work (Hydbring et al., 2010). First, we started by evaluating the effect of CDK2 
pharmacological inhibition by CVT-2584 on cell proliferation and growth of MYC/BCL-
XL-transduced murine HSCs in culture. CDK2 inhibition significantly reduced cellular 
proliferation and induced senescence, reflected by significantly higher SA β-gal positive 
cells treated with CVT2584. The reduction in tumor proliferation following CVT2584 
treatment was not accompanied with induction of apoptosis, as observed following the 
treatment with DNA damaging agent, ellipticine. We next proceeded to evaluate CDK2 
inhibition in vivo, by injecting the MYC/BCL-XL-transduced HSCs into lethally irradiated 
BALB/c mice. Treatment with CVT2584 via i.p injection resulted in a moderate, but 
significant, enhancement in survival compared to mice treated with vehicle. In an attempt 
to improve survival further, we performed the same experiments using a higher CVT2584 
dose, which resulted in a minor improvement of survival, in comparison to the vehicle. 
Further improvement in drug delivery and availability using minipumps did not have a 
profound effect on the overall survival. The aggressive nature of the initiated tumors and 
low bioavailability of the drug in vivo rendered higher margins of survival benefits 
challenging to achieve. Nevertheless, the pharmacological inhibition of CDK2 in vivo using 
CVT2584 significantly improved survival of the leukemic mice. Finally, we utilized an 
adjusted model to allow for slower AML progression, by injecting the MYC/BCL-XL-
expressing leukemic cells, harvested from leukemic mice, at lower cell number into sub-
lethally irradiated mice. In these experiments, we evaluated the potential of CVT2584 in 
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comparison to the FDA-approved and senescence-inducing drug CDK4/6 inhibitor, 
palbociclib. The treatment with either of these inhibitors resulted in a significant, and 
comparable, enhancement in survival, compared to vehicle treated mice.  Overall, these 
results demonstrate that CDK2 pharmacological inhibition in vivo was able to improve 
survival and delay tumor development. 
 
We next investigated the effects on tumor load in the AML mice. Previous work using this 
model showed that the mice exhibit extensive infiltration of leukemic cells in the bone 
marrow, spleen and liver tissues. Using flow cytometry, we examined the percentage of 
tumor cells in these tissues, sorted by CD11b/Gr1 or internal markers GFP and YFP, and 
observed a significant reduction in the leukemic cell population in response to CVT2584 
treatment in the bone marrow, spleen and liver at the day of sacrifice. Furthermore, the 
spleen weights of the mice were significantly lower than mice treated with vehicle. 
However, we did not observe clear differences in the histology of the spleen and liver 
tissues between the CVT- treated mice and the DMSO treated mice. These results show 
that CDK2 inhibition curbed the growth of the leukemic cells, contributing to improved 
overall survival.  Next, we evaluated the molecular changes triggered by CDK2 inhibition 
in tumor-bearing tissues. Co-immunostaining of proliferation markers Ki-67 and Ser-10-
phosphorylated histone H3 (p-H3S10) revealed a significant reduction in the proliferative 
index of tumor cells population in the spleen of CVT2584-treated mice. In addition, the 
reduction in Ki-67 and p-H3S10 was accompanied with reduction in the levels of cyclin A 
in the spleen. While we did not observe a reduction in MYC and BCL-XL protein levels, 
we observed reduction in phosphorylated Ser-62 MYC levels in response to CDK2 
inhibition, which falls in line with our previous in vitro work. Based on our hypothesis, we 
assumed that the effect of CDK2 inhibition on tumor survival and proliferation was a 
consequence of senescence induction in response to anti-CDK2 treatment. We therefore 
proceeded to evaluate senescence through various markers in the spleen tissues. The spleen 
tissues from CVT2584-treated mice showed a significant increase in SA β-gal staining. 
This was accompanied by reduction of pRB phosphorylation and induction of p21CIP1 and 
p19ARF protein levels, representing different markers of senescence.  Furthermore, we 
observe an induction in H3K9me3 histone marks in stained sections from CVT-treated 
mice, which was not observed in the vehicle-treated mice. In contrast, we did not observe 
signs of apoptosis following CVT-2584 treatment in vivo, in a similar fashion to our in vitro 




In paper II, we used a BRAFV600E/MycER-driven mouse lung tumor model, to further 
evaluate CDK2 role in senescence suppression and its effect on MYC-related functions in 
tumor cells. These mice carry the oncogenic BRAFV600E allele and tamoxifen-regulated 
Myc-ER fusion protein, which is activated by CRE recombinase. Delivery of adeno-CRE 
virus containing the CRE recombinase enzyme into the lungs of the mice results in the 
recombination of these loci in the infected cells, leading to the activation of BRAFV6OOE 
and MycER expression (Tabor et al., 2014). These mice were cross-bred with conditional 
CDK2 knockout mice, where the CDK2 locus is flanked with LoxP sites, which are 
recognized and excised by the CRE recombinase enzyme, leading to CDK2 deletion. In the 




CDK2 deletion, on top of BRAFV6OOE and MycER expression. Moreover, the activity of 
MycER is regulated through tamoxifen administration (TAM), which was delivered 
through the diet. Using this model, we first studied the consequences of CDK2 genetic 
deletion on the survival of the BRAFV600E/MycER-mice. There was a significant 
enhancement in overall survival of mice with BRAFV600E/MYC lung tumors lacking CDK2 
(CDK2FL/FL) compared to CDK2-proficient mice, with median survival of 127 days and 38 
days respectively. The survival benefit of CDK2 genetic depletion was also improved in 
comparison with CDK2 wildtype mice expressing BRAFV600E without TAM (MycER off). 
The haematoxylin and eosin (H&E) histopathological analysis revealed that the 
enhancement in survival coincided with significantly lower tumor burden in the CDK2-
depleted mice. To investigate the differences in tumor development, we studied the kinetics 
of tumor initiation and development at earlier time points. Our analysis showed a 
significantly lower tumor burden at 2, 3 and 4 weeks, following tamoxifen administration, 
in the BRAFV600E/Myc-ER/CDK2FL/FL cohort compared to the BRAFV600E/MycER cohort, 
indicating a delay in tumor development in response to CDK2 genetic depletion. In 
addition, our analysis showed a reduction in the number of overall tumors in CDK2-
deficeint mice at the 2 weeks time point, with negligible difference at the 3 and 4 weeks 
time points. To validate these results, we used the CDK2 pharmacological inhibitor Cyc065 
to block CDK2 activity in BRAFV600E/MycER mice. In this experiment, Cyc065 was 
administrated orally for 2 weeks, starting 2 weeks after tamoxifen administration. The 
results show a similar reduction in tumor burden to the kinetic experiment between the 
Cyc065-treated and vehicle-treated mice. These results demonstrate that CDK2 genetic 
depletion enhances survival, delays tumor development and reduces tumor burden in 
BRAFV600E/MycER lung tumors. 
 
Next, we investigated the occurrence of senescence in CDK2 wt and CDK2 knockout 
BRAFV600E/MycER tumors. Using Ki67 immunohistochemistry staining, our results 
showed a significant reduction in the proliferative index in BRAFV600E/MycER tumors with 
depleted CDK2 as well as after pharmacological inhibition of CDK2. Evaluating other 
senescence markers, we observed an increase in p21 and H3K9me3 staining in the CDK2-
deficient cohorts, both at the endpoint and at the 3 and 4 weeks time points, as well as in 
Cyc065-treated mice. In addition, when investigating apoptosis using in situ cell death 
detection assay (TUNEL), our results showed a complete absence of apoptosis induction in 
all of our cohorts, further indicating that the differences observed between CDK2 wildtype 
tumors and CDK2 depleted tumors were a consequence of senescence induction. Moreover, 
analysis on whole lung lysates from the 4 weeks time point by immune blot showed an 
induction of p21 expression and reduction in pRB phosphorylation and PCNA, an S phase 
proliferation marker, in BRAFV600E/MycER mice with deficient CDK2 compared with 
wildtype CDK2. Overall, our molecular analysis demonstrates that CDK2 depletion 
induced senescence in BRAFV600E/MycER-driven lung tumors, which was correlated with 
prolonged survival and delayed tumor development. 
 
To gain more insight into the molecular changes elicited by CDK2 ablation, we performed 
RNAseq analysis on lung tissues obtained from the 4-weeks time point. Our unsupervised 
hierarchical clustering analysis of the differential gene expression showed a discrete 
clustering of the upregulated and downregulated genes, and where MycER and CDK2 each 
show counteracting effects on gene expression. Gene enrichment and gene ontology 
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analysis of the gene expression data was then performed to gain more information on the 
different changes in pathways and processes involved in the observed phenotypes. Gene 
ontology analysis using the mouse reference genome, showed an upregulation in genes 
involved in metabolic processes in response to MycER activation by TAM compared to 
vehicle administration in BRAFV600E/MycER mice with wildtype CDK2, as expected. 
Additionally, MycER activation led to downregulation of genes involved in the 
inflammatory response, consistent with recent publications regarding MYC role in cancer 
immunity (Casey et al., 2016; Kortlever et al., 2017; Muthalagu et al., 2020; Sodir et al., 
2020). Comparing the gene expression of the BRAFV600E/MycER groups with wildtype 
CDK2 vs. depleted CDK2 using the gene ontology database, we observed that CDK2 
ablation led to induction of genes involved in different immune functions, including innate 
immunity and B cell activation. To confirm these results, we utilized the MetaCore gene 
expression database, which contains mouse sequencing data. Our analysis confirmed that 
CDK2 depletion in BRAFV600E/MycER tumors resulted in an upregulation of the immune 
cell compartment. Additionally, analysis of differential gene expression using the 
PANTHER database showed an upregulation of innate immune response, B cell activation 
and phagocytosis. To investigate correlations with senescence-induced pathways, we 
analyzed the gene expression levels of different genes involved the senescent-associated 
secretory phenotype (SASP), as well as MYC signalling and other senescence-related 
processes, using the RNAseq reads. Our data showed differences in the expression pattern 
of SASP-related genes of relevance for the immune response. For instance, CXCL9, 
CXCL14 and IFN-γ receptor were upregulated in BRAFV600E/MycER CDK2 KO mice 
induced with TAM, while CXCL1 and CSF2 expression was induced in corresponding 
TAM-treated CDK2 wildtype mice. Among these, CXCL9 and CXCL14 are 
chemoattractants that recruit and activate lymphocytes and monocytes respectively, IFN-γ 
receptor is expressed on macrophages and other cells, CXCL1 promotes angiogenesis and 
CSF2 is involved in granulocyte and monocyte maturation. In addition, the expression of 
negative immune regulators ENTDP1 (CD39), PD-L1 and SPP1 was downregulated in 
BRAFV600E/MycER mice with depleted CDK2 compared to mice with wildtype CDK2. 
ENTDP1 is involved in the immune suppression activity exerted by regulatory T cells 
(Tregs), while PD-L1 is a well-known inhibitory checkpoint molecule involved in the 
suppression of CD8 cytotoxic T cells. In addition, SPP1 is also involved in promoting 
metastasis and pro-tumor immunity. Next, we examined the expression of different immune 
cell markers in the different groups. We observed an upregulation of the general 
macrophage marker CD68, in response to CDK2 loss, while T cell markers CD3g and 
CD3e, as well as MDSCs marker Ly6C were downregulated by MYC activation, regardless 
of CDK2 status. Worthy of note, we also observed an upregulation in M2-like macrophage 
marker MRC1 in the BRAFV600E/MycER cohort with depleted CDK2, compared to 
BRAFV600E/MycER cohort with wildtype CDK2. Finally, the analysis of the RNAseq reads 
showed an upregulation in the expression of senescent markers p21 and Lamin B1 in 
CDK2-depleted mice, confirming our results obtained from immunohistochemistry and 
protein immune blot analysis. Taken together, our gene expression analysis revealed that 
CDK2 loss led to apparent immune activation and diverse effects on the cytokines and 
chemokines expression profile in the BRAFV600E/MycER-driven lung tumors. 
 
Next, we opted to study if the phenotype and transcriptional changes observed in our lung 




HCC364 lung cancer cell line, which carry a BRAFV600E mutation and in which we 
transduced MycER using a viral vector, thereby creating a similar model to the one used in 
our animal work. First, we evaluated senescence induction in response to CDK2 using 
siRNA knockdown. MycER was first activated by 4-hydroxytamoxfien (4-OHT) for 48 
hrs, followed by CDK2 siRNA knockdown for 72 hrs. Our results showed that CDK2 
knockdown in these cells led to senescence induction, characterized by increased SA β-gal 
activity and induction of p21 protein levels, exhibiting similar response to our previous 
results in vivo. We then proceeded to investigate the changes in the expression of different 
cytokines, chemokines and immune modulators in response to CDK2 knockdown, using 
RT-qPCR. We observed a downregulation of CXCL1, CSF2 and CCL-2 expression in 
response to CDK2 knockdown, irrespective of MycER status. Moreover, the expression of 
IL-6, IL-8, IL-1β and MMP3 were downregulated by CDK2 knockdown in MycER active 
cells. In contrast, several transcription factors involved in the regulation of the 
inflammatory response, including STAT3, STAT5A and IFN-γ were upregulated in 
response to CDK2 knockdown. Meanwhile, the expression of CXCL14, IL1A and 
interferon response factors IRF-5 and IRF-7 were downregulated following CDK2 
knockdown. Finally, we observed a downregulation in the expression of the negative 
immune modulators ENTDP1 and PD-L1 expression following CDK2 knockdown, while 
CD47 expression was upregulated further in response to CDK2 knockdown. In summary, 
our results confirm that CDK2 knockdown induces senescence and alter the immune profile 
of HCC364-MycER human cell line, in a similar fashion to our in vivo results. 
 
To validate our results obtained from the RNAseq data analysis and cell culture work, we 
examined the immune cell population in tumor tissues obtained from the different in vivo 
experiments using co-immunofluorescence staining. The tumor sections were stained for 
CD3 (T cell marker), PAX5 (B cell marker) and IBA1 (macrophage marker). The analysis 
of the stained sections at the end point showed a significant increase in T cell and 
macrophage infiltration in the lung tissues of BRAFV600E/MycER mice with depleted 
CDK2. This infiltration was irrespective of MycER status in the tumors. In addition, further 
analysis revealed that the mice had significantly higher number of T cells and macrophages 
infiltrating the tumors. The analysis of the B cell population showed a significant increase 
in B cell infiltration in the lungs of CDK2 depleted mice with inactive MycER, while those 
with active MycER was higher but did not reach significance. The analysis of the tumor 
population at the 4 weeks time point showed a similar trend, albeit less pronounced 
compared to the end point experiment. Analysis by flow cytometry confirmed an increased 
presence of activated CD8 T cells in the lungs with CDK2-depleted tumors even with active 
MycER, while presence of activated NK cells increased in lungs CDK2 depleted tumors 
when MycER was inactive, but were suppressed by active MycER irrespective of CDK2 
status. To assess the effect of MYC inactivation on the tumor burden and immune cell 
population, we carried an experiment where we treated BRAFV600E/MycER CDK2 KO 
mice with TAM for 4 weeks, after which we either sacrificed the mice, or kept on them on 
TAM or normal diet for an additional 10 days. The histopathological analysis of the lung 
tumors showed a massive reduction in tumor burden following MYC inactivation for 10 
days compared to 4 weeks group and the group with continued active MycER, with over 
50% barely showing any signs of tumors in the lungs. We also observed a reduction in Ki67 
positive tumor cells and in p21 staining in these mice. This was accompanied with a 
decrease in H3K9me3 staining, suggesting a possible clearance of senescent cells in the 
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lungs. Furthermore, analysis of the different immune populations did not show any 
significant change in the overall infiltration of T cells and macrophages in the lung between 
the different groups. However, we observed a significant reduction in the B cell population 
in the TAM withdrawal group, compared to the control groups. Furthermore, analysis of 
the immune cell population within the tumor area showed a significant increase in 
macrophage infiltration following MYC withdrawal. Finally, our evaluation of apoptosis 
induction using in situ death assay did not indicate any presence of apoptotic cells in any 
of the experimental groups. Overall, the results show that MYC deactivation in CDK2-
depleted tumors led to massive tumor regression and reduction in overall number of 
senescent cells, with no apparent apoptosis induction. These changes coincided with an 
increase in macrophages infiltration into the tumor area, suggesting a possible clearance of 
senescent tumor cells by macrophages in response to MYC withdrawal. Another possibility 
is that elimination of senescent tumor cells upon MYC withdrawal was the result of 
activation of cytotoxic T cells and/or NK cells, which then were phagocytized by 
macrophages.  
 
Our work confirms that targeting CDK2 induces senescence in MYC-driven tumors in vivo 
and shows that this correlates with reduced tumor growth and proliferation, resulting in 
improved survival. It is therefore a promising concept that potentially can be utilized to 
combat MYC function is cancer. The pharmacological inhibition of CDK2 in our leukaemia 
model delayed tumor onset, triggered a senescence response and reduced tumor burden. 
The survival benefits were significant, but modest, which can be attributed to the 
aggressiveness of the model and the limitations with the CDK2 inhibitors available 
currently render it very difficult to achieve a very long durable response in this system. 
Similarly, CDK2 depletion in the BRAFV600E/MycER-driven lung tumor model confirmed 
the importance of CDK2 in senescence suppression in tumors driven by MYC. The loss of 
CDK2 triggered senescence, inhibited tumor growth and significantly prolonged the 
survival. Furthermore, we uncovered a novel role for CDK2 in immunomodulation in the 
BRAFV600E/MYC-driven lung tumors. This was difficult to evaluate in the AML model due 
to immune cell depletion after irradiation, which is necessary in this system prior to HSC 
transplantation. This immune modulatory function of CDK2 seems to affect different 
immune cells, including T cells, NK cells, B cells and macrophages. Interestingly, our flow 
cytometry analysis showed a significant increase in activated CD8 T cells in lungs in 
response to CDK2 depletion in tumors, irrespective if MycER was active or inactive. On 
the other hand, active MycER suppressed NK cell activation in agreement with previous 
reports (Kortlever et al., 2017; Sodir et al., 2020; Swaminathan et al., 2020), and this 
occurred irrespective of CDK2 status, while increased number of activated NK cells were 
observed after CDK2 depletion if MycER was inactive. This raises the question whether 
the tumor regression observed in CDK2-depleted tumors after deactivation of MYC, can 
be explained by combined T cell and NK cell killing of the lung tumor cells? If so, these 
observations suggest that the dual MYC and CDK2 inhibition might achieve a strong T 
cell- and NK cell-mediated response in MYC-driven tumors. This warrant further 
investigation. Worthy of mention, blocking CDK2 in MYCN-amplified neuroblastoma 
have been shown to induce massive apoptosis, and not senescence, suggesting a tissue-
specific response in the effect and outcome of CDK2 inhibition (Molenaar et al., 2009). 
Regardless, our work demonstrates that CDK2 inhibition is a promising strategy in tumors 




neuroblastoma (Bolin et al., 2018; Molenaar et al., 2009). It can also be effective in tumors 
with cyclin E amplification and/or overexpression and tumors resistant to CDK4/6 
inhibition, as CDK2 is reported to be involved in the resistance mechanism to CDK4/6 
inhibitors (Herrera-Abreu et al., 2016). It also opens the possibility of using CDK2 
inhibitors in combination with immunotherapies to boost the immune response. This work 
also warrants the need to develop more specific and effective CDK2 inhibitors as anti-
cancer therapies, with a focus on MYC-driven tumors.      
 
 
3.2   Small molecule inhibitors MYCMI-6 and MYCMI-7 bind MYC, selectively block 
MYC:MAX interaction, abrogate tumor cell growth and induce apoptosis in MYC-
dependent tumors without killing normal cells (Papers III and IV) 
 
The transcriptional regulation functions of MYC that are required for its cancer-promoting 
activity are dependent on the dimerization with its partner MAX. The crucial role of this 
dimerization for MYC biological activity prompted us to identify and characterize 
inhibitors that can block the interaction between MYC and MAX, thus directly inhibiting 
MYC functions. To achieve this, we carried out a cell-based screen using the bimolecular 
fluorescence complementation (BiFC) assay. In this assay, full-length MYC and MAX 
were fused to the non-fluorescent C- and N-terminus fragments of yellow fluorescent 
protein (YFP), respectively, which when brought in close proximity due protein-protein 
interactions restore the YFP fluorescence signal (Grinberg et al., 2004; Hu et al., 2002). We 
co-transfected these constructs into HEK293 cells, and validated the assay by using a MYC 
construct lacking the bHLHZip domain (MYCΔbHLHZip) required for dimerization with 
MAX. While the full length MYC-fusion resulted in a clear positive fluorescence signal 
together with the MAX fusion protein, using the MYCΔbHLHZip-fusion together with the 
MAX-fusion did not produce any positive signal, highlighting the high specificity of the 
assay. We then proceeded to use this technique to screen a small library of 1990 chemical 
compounds from the NCI/DTP repository for substances that can inhibit MYC:MAX 
dimerization. 6 compounds, (MYCMI-2, MYCMI-6, MYCMI-7, MYCMI-9, MYCMI-11 
and MYCMI-14), with over 40% reduction in MYC:MAX specific positive signal as 
potential inhibitors of MYC:MAX interaction were identified, and were termed 
MYC:MAX inhibitors (MYCMI). The BiFC results were further validated by the use of 
protein-fragment complementation assay (PCA) that utilizes split Gaussia princeps 
luciferase (GLuc) (Remy and Michnick, 2006). The results show that the all 6 compounds 
significantly decreased the luciferase signal at 25 µM compared to cells treated with 
previous MYC:MAX inhibitor 10058-F4 used at 64 µM. Analysis of the effect of these 
compounds on the MYC protein level showed that two compounds, MYCMI-7 and 





In paper III, we focused on MYCMI-6, MYCMI-11 and MYCMI-14 for further 
investigation.  In order to evaluate the inhibitory effects of these compounds on the 
endogenous cellular MYC:MAX interaction, we utilized in situ proximity ligation assay 
(isPLA), which is used to study protein-protein interaction in cells. Our results show that 
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cells treated with MYCMI-6, MYCMI-11 or MYCMI-14 exhibited a significant reduction 
in fluorescent dots, representing MYC:MAX complexes, in comparison with DMSO, with 
less than 1.5 µM IC50 for MYCMI-6 and 6 µM IC50 for MYCMI-11 and MYCMI-14. 
These effects were not observed for FRA1:JUN interactions, bZip transcription factors 
interacting in a similar way, indicating that these compounds are indeed selective towards 
MYC:MAX complexes. Additionally, co-immunoprecipitation showed a clear reduction in 
MYC:MAX protein complexes as early as 3 hrs post treatment with MYCMI-6. Moreover, 
treatment with MYCMI-6 in U2OS-MycER cells significantly attenuated MYC 
transcriptional activity induced by 4-hydroxy-tamoxifen, as indicated by the significant 
reduction mRNA levels of MYC target genes, ODC1, RSG16 and CR2, while MYCMI-11 
and MYCMI-14 had more mild inhibitory effects. Next, we proceeded to assess the ability 
of these inhibitors to directly inhibit the formation of the MYC:MAX heterodimers using 
recombinant bHLHZip portions of MYC and MAX proteins in microscale thermophoresis 
(MST) and surface plasmon resonance (SPR) assays. MST is a thermophoresis-based assay 
in which the ability of a fluorescently labelled molecule to move in a microscopic 
temperature gradient is measured. This mobility is subject to changes caused by binding to 
other molecules. In the SPR assay, the protein of interest is immobilized on a chip, and the 
ligand of interest is allowed to flow over the immobilized protein. Binding between the 
protein and the ligand causes a change in the surface plasmon resonance that can be 
measured (Schasfoort and Tudos, 2008). The MST results showed that all three compounds 
weakened recombinant MYC bHLHZip interaction with the fluorescently labelled 
recombinant MAX bHLHZip, compared with DMSO. Additionally, MYCMI-6 selectively 
inhibited MYC:MAX dimers with a Kd of 4.3 ± 2.9 µM, with only a minor effect on 
MAX:MAX dimers, suggesting a high level of selectivity for MYC:MAX dimers over 
MAX:MAX dimers. In the SPR assay, MYCMI-6 inhibited MYC bHLHZip:MAX 
bHLHZip dimer formation at an IC50 of 3.8+/-1.2 µM, while the MYC:MAX inhibitors 
10058-F4 and KJ-Pyr-927 had little or no effect at 10 µM. To determine whether MYCMI-
6 binds directly to MYC or MAX, we performed MST and SPR using recombinant MYC 
and MAX bHLHZip domains. We observed alterations in thermophoresis from 1 µM of 
MYC in a titration experiment, after preincubation with 3 µM MYCMI-6, while MAX 
failed to cause any change at these concentrations, nor did the control proteins BCL-XL 
and bovine serum albumin (BSA). SPR analysis using immobilized MYC bHLHZip 
showed a KD value of 1.6 ± 0.5 µM, while the MYC:MAX inhibitors 10074-G5 and the 
10058-F4 analogue #474 showed KD values of 28 and 15 µM respectively. MYCMI-6 
binding to control proteins MAX and MXD1 (MAD1), which both are very similar to MYC 
in structure, and to p53 and YFP was not measurable. These results demonstrate that 
MYCMI-6 binds directly and selectively to MYC with single digit µM affinity.  
 
Our next step was to evaluate the potency of MYCMI-6, -11 and -14 in inhibiting the 
growth of MYC-driven tumor cells. To examine this, we used a panel of neuroblastoma 
cell lines with or without MYCN-amplification and Burkitt’s lymphoma cells with MYC 
translocation. Our results show that MYCMI-6 efficiently suppressed the growth of 
MYCN-amplified Kelly, IMR-32 and SK-N-DZ neuroblastoma cells, with IC50 of 2.5-6 
µM, while MYCN-non-amplified SK-N-F1, SK-N-RA and SK-N-AS neuroblastoma cells 
were less sensitive. Our results also show that MYCMI-6 strongly inhibited anchorage-
dependent growth of MYCN-amplified neuroblastoma cells. Similarly, MYCMI-6 




Additionally, MYCMI-6 inhibited MYCN:MAX dimerization in neuroblastoma cells as 
observed by isPLA and significantly decreased the expression of MYCN target genes. Next, 
we evaluated the effect of MYCMI-6 on MYC-dependent cell growth. To study this, we 
utilized the Rat immortalized fibroblast cell line, designated as TGR-1, a MYC-null TGR-
1 cell line, designated as HO15.19, and a MYC reconstituted HO15.19 cell line, designated 
as HOMYC3. We observed a sharp decline in viability of TGR-1 and HOMYC3 cells as 
measured by WST-1 assay in response to MYCMI-6 treatment, while MYC-null HO15.19 
did not exhibit any effects at the concentrations used. These results show that MYCMI-6 
mechanism of action is indeed MYC dependent. Moreover, computational analysis of IC50 
of the NCI-60 human tumor cell lines database for MYCMI-6 showed that cells with higher 
MYC expression were significantly more likely to respond to MYCMI-6 than cells with 
low MYC expression. Furthermore, our evaluation of MYCMI6 effects on normal cells vs 
tumor cells showed that MYCMI-6 treatment induced apoptosis in neuroblastoma cells, 
while it was not cytotoxic for normal cells, such as IMR-90 and BJ normal human 
fibroblasts. Finally, treatment MYCMI-6 in MYCN-amplified SK-N-DZ xenograft mouse 
model showed a massive induction of apoptosis, necrosis, and vasculature hemorrhage, 
which was accompanied by reduction in tumor cell proliferation and in microvascular 
density. Importantly, analysis of MYC:MAX dimerization by isPLA in tumor tissue 
revealed a reduction in dimerization within the MYCMI-6 treated tumors compared to 




In paper IV, we proceeded to focus and characterize the small molecule inhibitor MYCMI-
7. In a similar fashion to our approach in the MYCMI-6 paper, we validated the efficiency 
of MYCMI-7 in inhibiting MYC:MAX dimerization, its ability to bind MYC and MAX, 
and its effect on tumor cell growth and survival in vitro and in vivo, using different cancer 
cell lines and tumor mouse models. Following the initial analysis by BiFC assay, Gluc assay 
and western blot mentioned earlier, we validated the effect of MYCMI-7 on MYC:MAX 
interaction using isPLA in MCF7 breast cancer cells. The results showed a strong reduction 
in MYC:MAX interaction signal following treatment with 5 µM MYCMI-7 for 24 hrs. 
Moreover, a co-immunoprecipitation for MYC and MAX showed that MYCMI-7 reduced 
the level of MYC:MAX complexes as early as 1 hr post treatment, with increasing 
inhibitory effect on MYC:MAX interaction while no reduction of total MYC protein level 
occurred up to 4 hrs post treatment. Chromatin immunoprecipitation (ChIP) analysis in 
MCF7 breast cancer cells following 6 hrs of 5 µM MYCMI-7 treatment resulted in 
reduction in MYC association with the MYC target ODC1 gene promoter, starting at 2 hrs 
and steadily decreasing up to 24 hrs. The de-association of MYC from ODC1 promoter 
coincided with a reduction in ODC1 expression. To determine whether MYCMI-7 binds 
directly to MYC, SPR assay using a recombinant MYC bHLHZip protein domain 
immobilized on the chip demonstrated that MYCMI-7 binds to MYC in a dose-dependent 
manner, with a KD of ~ 4 µM. These results provided evidence that MYCMI-7 binds MYC 
directly and rapidly, as well as specifically block MYC:MAX dimerization in cells and low 
µM concentrations. 
 
When examining the effect of MYCMI-7 on MYC protein level following longer 
treatments (24-48 hrs), we observed a reduction in MYC and MYCN proteins levels in 
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different cancer cell lines. To investigate the mechanism behind this, we performed RT-
qPCR analysis at different time points in MCF7 breast cancer cell line, following treatment 
with 5 µM MYCMI-7, which showed that MYCMI-7 treatment did not affect MYC mRNA 
levels. Next, we evaluated if MYCMI-7 decreased MYC protein level, and whether this 
involved SCFFBXW7 E3 ligase mediated-degradation. For this, HCT116 colon cancer cell 
line with deficient FBXW7 was used. To investigate the dynamics of MYC protein 
degradation by MYCMI-7, we performed cycloheximide (CHX) chase assay to examine 
MYC protein level, where CHX was added to block new protein synthesis following 
MYCMI-7 treatment after which the rate of decay of MYC protein was monitored. This 
assay provides information on rate turnover in the cell. Our results showed that MYC 
protein turnover was increased in FBXW7 wildtype HCT116 cells, but not in FBXW7-
defecient HCT116 cells, following treatment with MYCMI-7. This effect was not due to a 
general increase in FBWX7 activity, since the protein levels of cyclin E, another FBXW7 
target, was unchanged. Examination of MYC Thr-58 and Ser-62 phosphorylation, the 
binding sites for FBXW7, by western blot did not show any increase in response to 
MYCMI-7. In addition, expression of MYC in the T58A and S62A mutants was still 
reduced in response to the treatment. These results suggest that MYCMI-7-mediated 
downregulation of MYC protein levels were dependent on FBXW7, but through an indirect 
mechanism and not through the classical FBXW7 mechanism. 
 
We next evaluated the effect of MYCMI-7 on MYC-dependent cell growth. To study this, 
we utilized similar approach to the one described in paper III, using the TGR-1, H015.19 
and HOMYC3 cell lines. Similar to MYCMI-6, treatment with MYCMI-7 for 48 hrs 
showed a drastic decline in viability of TGR-1 and HOMYC3 cells as measured by WST-
1 assay, with IC50s of 2 µM, while MYC-null HO15.19 remained unaffected, even at 
higher MYCMI-7 concentrations. Treatment with ellipticine, a DNA intercalator/Top2 
inhibitor with similar structure as MYCMI-7, uniformly reduced the viability of all three 
cell lines. Next, we continued to evaluate MYCMI-7 ability to inhibit the growth of MYC-
driven cancer cell lines. MYCMI-7 exhibited significantly stronger inhibitory effects on 
cell growth and viability in MYCN-amplified compared to MYCN-non-amplified 
neuroblastoma cells. Strong reduction in tumor cell growth was also observed in Burkitt’s 
lymphoma cell lines upon treatment with MYCMI-7. Additionally, analysis of MYCMI-7 
IC50 and expression data for the NCI-60 diverse human tumor cell line panel, described 
previously in paper III, showed a strong correlation between the response to MYCMI-7 and 
MYC cellular levels; 63% of cell lines with high MYC expression were responsive to 
MYCMI-7 compared to only 21% responders in cells with low MYC levels. Moreover, we 
investigated the ability of MYCMI-7 to block transformation of primary rat embryonic 
fibroblasts (REFs) transfected with RAS and MYC. The results showed that MYCMI-7 
blocked foci formation and colony formation in semi-solid medium at a concentration of 
0.5 µM. Similar IC50 value was observed for 3D cultures of MYC-amplified SK-N.DZ 
neuroblastoma cells.  We next studied changes in global mRNA expression elicited by 
MYCMI-7 treatment using RNAseq analysis in MCF7 breast cancer cells. Gene set 
enrichment analysis (GSEA) showed downregulation of the MYC and E2F target gene 
profiles following MYCMI-7 treatment. This was accompanied by upregulation of genes 
involved in the inflammatory response, such as NFκB, consistent with recent reports 
implicating MYC in immune suppression in different tumors. These results show that 




    
To study the effect of MYCMI-7 on the cell cycle, we utilized the P493-6 B cell line 
containing a doxycycline-regulated MYC, as well as normal REFs. Cell cycle analysis by 
flow cytometry showed an accumulation in G1 in P493-6 cells treated with MYCMI-7, 
accompanied with a increase in apoptotic sub-G1 population. In contrast, MYCMI-7 
treatment induced cell cycle arrest in normal REFs but no apoptosis, as evident by the 
accumulation of cells in G1 without signs of a sub-G1 population. Importantly, MYCMI-7 
treatment did not cause apoptosis in immortalized MYC-deficient Rat1 HO15.19 cells, but 
induced apoptosis in a dose-dependent manner in parents TGR1 cells and the HOMyc3 
MYC-deficient cells reconstituted with MYC. Note that MYCMI-7 reduced cell 
proliferation and metabolic activity of human normal dermal fibroblasts (HNDF) and 
primary normal human epidermal melanocytes (NHEM) but did not reduce viability or 
induced apoptosis in these cells. Overall, MYCMI-7 halted the proliferation and caused cell 
cycle arrest in both normal and tumor cells but lead to apoptosis only in tumor cells and 
immortalized cells, thereby showing a good therapeutic window. 
 
Giving the structural similarities between MYCMI-7 and ellipticine, which has been 
described as a topoisomerase 2 (Top2) inhibitor and DNA intercalator, we sought to 
investigate if MYCMI-7 inhibits Top2 and whether this can explain its anti-tumor effects. 
To do so, we first evaluated if MYCMI-7 can inhibit Top2 activity in vitro using Top2 
decatenation assay. In this assay, Top2 decatenate kinetoplast DNA, converting 
interlocking DNA rings into individual rings that can be examined with agarose gel 
electrophoresis. Our results show that MYCMI-7 exhibited inhibitory effects on Top2 
activity at a concentration of 30 µM, reaching complete inhibition at 100 µM. In 
comparison, the Top2 inhibitor doxorubicin (DOX) exhibited this effect starting at 3 µM 
and reaching complete inhibition at 10 µM, while ellipticine and the topoisomerase 1 
(Top1) inhibitor camptothectin did not show any inhibitory effect on Top2 activity at any 
given concentration. Moreover, our in vitro examination of MYCMI-7 ability to intercalate 
with the DNA showed that it did do so at low µM concentrations in a similar manner as 
ellipticine. However, in contrast to ellipticine, this did not result in any induction of p53 or 
ATM phosphorylation, or reduction in MYC mRNA levels in cells at active concentrations 
of MYCMI-7. Moreover, depletion of p53 in HCT116 cells did not affect MYCMI-7-
induced growth inhibition/viability. To further evaluate if MYCMI-7 activity is dependent 
on Top2, we performed isPLA on HCT116-TIR-AID cells, which contain an auxin-
regulatable Top2, in which auxin treatment results in rapid degradation of Top2. The cells 
were pre-treated with auxin to deplete Top2 and then subjected to MYCMI-7 treatment for 
6 hrs, before isPLA examination. The results demonstrated that Top2 depletion did not 
affect MYC:MAX dimerization nor did it abrogate the inhibitory effects of MYCMI-7 on 
MYC:MAX. We further validated these results by siRNA-mediated knockdown of Top2 
in MDA-MB-231 breast cancer cell line. Top2 knockdown did not abolish MYCMI-7’s 
ability to decrease cell viability, nor did it change the IC50 of MYCMI-7, arguing against 
a role of Top2 in MYCMI-7 mechanism of action. Collectively, these results suggest that 
MYCMI-7 does not primarily induce DNA damage and its MYC inhibitory effects are not 
dependent on Top2 or p53. 
 
In the final part of the project, we evaluated MYCMI-7’s anti-tumor activity in patient-
derived tumor cells in culture and in mouse tumor models in vivo. First, we investigated the 
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efficacy of MYCMI-7 using a collection of 42 primary patient-derived glioblastomas 
representing different subtypes. MYCMI-7 treatment strongly reduced the growth/viability 
of these cells at a concentration around 1 µM, regardless of the tumor subtype. Additionally, 
MYCMI-7 inhibited the growth of several primary patient-derived AML cells in a dose-
dependent manner, with IC50 ranging between 0.15-1.3 µM, showing significantly stronger 
inhibitory effects than 10058-F4, JQ1 and cisplatin, a drug used in the clinic for AML 
patients. Next, MYCMI-7 was validated in several MYC-driven mouse tumor models. 
Using the MYC/BCLXL-driven acute myeloid leukemia (AML) model described in paper 
I, we evaluated the effects of MYCMI-7 treatment on tumor load, progression, and overall 
survival. At day 15 post tumor cells injection, we observed significantly lower tumor load 
in the spleen and bone marrow of MYCMI-7-treated mice compared to the vehicle-treated 
cohort, indicating a delay in tumor progression in response to MYCMI-7 treatment. 
Similarly, we observed significantly lower tumor load in the bone marrow and spleen at the 
survival endpoint. Additionally, mice treated with MYMI-7 had less histologically 
disorganized spleen structure, with less infiltrating leukemic cells, compared to vehicle-
treated mice. Importantly, MYCMI-7 treatment was tolerable, as body weight of treated 
mice did not get affected by the treatment. The tumor cells in the spleen of MYCMI-7-
treated mice also exhibited lower levels of MYC expression than control mice. However, 
this obvious response to MYCMI-7 did not improve the overall survival of the mice, which 
might be attributed to extreme aggressiveness of these tumors along with suboptimal 
delivery and limited bioavailability of MYCMI-7 in vivo using i.p route. In addition, our 
evaluation of MYCMI-7 turnover in the plasma of mice showed a rather short half-life of 
1.5 hrs, which explains part of the poor effect on survival in this aggressive model. In 
summary, MYCMI-7 inhibited MYC/BCL-XL-driven tumor growth in vivo with tolerable 
side effects. Finally, we examined the anti-tumor effect of MYCMI-7 in mouse xenograft 
tumor models, using human breast cancer and MYCN-amplified neuroblastoma cell lines. 
MYCMI-7 was delivered via intra-tumoral injections, every 4 days, to avoid the MYCMI-
7 delivery issues observed after i.p injection in the AML model. The results showed that 
MYCMI-7 inhibited tumor growth and improved the overall mouse survival in both 
xenografts models. In addition, immunohistochemistry analysis of the MDA-MB.231 
tumor sections revealed that MYCMI-7 treatment reduced MYC and Ki67 expression, and 
induced apoptosis as evidenced by annexin V staining and the expression of caspase 3. 
These changes were also accompanied by reduction CD31 expression, indicating a decrease 
in microvasculature. Furthermore, we observed massive apoptosis and necrosis and strong 
reduction in MYCN expression in MYCN-amplified SK-N-DZ tumors in response to 
MYCMI-7 treatment. 
 
In summary, we observed that MYCMI-6 and MYCMI-7 bound directly to MYC in vitro, 
and inhibited MYC:MAX protein interaction in cells at low µM concentrations. Both of 
these inhibitors blocked tumor cell growth and induced cell death in tumor cells in a MYC-
dependent manner, while resulting in growth arrest, without cytotoxicity, in normal cells. 
Furthermore, MYCMI-6 and/or MYCMI-7 inhibited tumor growth and reduced 
MYC/MYCN activity/expression in mouse tumor models of AML, breast cancer and 
neuroblastoma without giving severe side effects. In the xenograft models, MYCMI-6 and 
MYCMI-7 triggered apoptosis/necrosis and MYCMI-7 improved overall mouse survival. 
The latter remains to be investigated for MYCMI-6. Enhancement of MYCMI-6 and 




these molecules are important steps for further development towards a potent anti-MYC 
drug for cancer treatment of patients in the clinic. The efficiency of both compounds in 
blocking MYC:MAX dimerization in the different cell lines we used is quite comparable 
and more potent than any of the previous MYC:MAX inhibitors, such as 10058-F4, 10074-
G5, MYCi361, MYCi975, KJ-Pyr-9 and others (Clausen et al., 2010; Han et al., 2019; Hart 
et al., 2014; H. Wang et al., 2007). Similarly, MYCMI-6 and MYCMI-7 affinity for MYC 
is superior to that of 10074-G5, 10058-F4, and F4 analogue #474 reported in other studies 
(Müller et al., 2014). Only MYCi361 and MYCi975 were reported to have similar affinity 
to MYC, although the method used to assess that is different and indirect, which is difficult 
to compare (Han et al., 2019). Despite the similarities in the outcome of MYCMI-6 and 
MYCMI-7 treatment regarding tumor growth, they appear to operate through different 
mechanisms. Unlike MYCMI-6, MYCMI-7 decreased MYC protein level in different cell 
lines. This is similar to what was observed in response to treatment other MYC:MAX 
inhibitors, such as 10058-F4, 10074-G5 and sAJM589 (Choi et al., 2017; Clausen et al., 
2010; Müller et al., 2014). This effect of MYCMI-7 on MYC levels, which appears to 
depend on FBXW7, is yet to be understood. For instance, MYCMI-7 did not affect the 
phosphorylation status of Thr-58 or Ser-62 on MYC, which plays an important role in 
FBXW7-mediated MYC degradation. In comparison, MYCi361 and MYCi975 treatment 
triggered MYC phosphorylation at Thr58 and subsequent degradation of MYC (Han et al., 
2019). The difference between MYCMI-6 and MYCMI-7 with respect to MYC turnover 
can be possibly due to a difference in the binding mode and its effect on MYC protein 
folding. It’s also possible that MYCMI-7 has off target effects that affects MYC turnover, 
which requires further investigation. We consider the former possibility more likely 
considering that many other MYC:MAX inhibitors reduced MYC levels. Moreover, a 
recent study by Mathsyaraja et al. showed that MYC protein levels were significantly 
reduced upon MAX deletion in normal and Eµ-MYC premalignant B cells, suggesting that 
the interaction with MAX stabilizes MYC (Mathsyaraja et al., 2019). On the other hand, 
the fact that MYCMI-6 does not affect MYC protein level provide a molecular tool to 
evaluate MYC function independent of MAX. Collectively, both of these compounds 
inhibited MYC:MAX interaction selectively, abrogate MYC-dependent tumor cell growth 











4   Summary and Conclusions 
 
MYC have been shown to be crucial for many different aspects of tumor development, 
contributing to most of cancer hallmarks, and deregulation of MYC is often associated 
with aggressive disease, resistance to treatment and poor outcome in human cancer. One 
of the reasons for this is that MYC plays such an important role as a transcription factor 
in many essential cellular processes of relevance for tumor development. This thesis has 
paid particular interest in two processes that relatively recently was shown to be under 
MYC regulation: cellular senescence and immune modulation. The growing evidence of 
MYC playing a central role in cancer and therapeutic outcome sparked the interest in 
developing different strategies to block MYC functions. The disordered nature of the 
MYC protein structure and its lack of enzymatic activity or druggable pockets, however, 
render this very challenging, and MYC has been considered “undruggable”. To block 
MYC and its functions, different approaches have been suggested, ranging from blocking 
MYC transcription, interfering with its posttranslational modifications to inducing its 
protein degradation. Interestingly, to function as a transcription factor, MYC needs to 
interact with a number of partner proteins. Hence, targeting the interaction between MYC 
and partner proteins or targeting druggable enzymatic activities of partner proteins, when 
possible, are plausible ways of interfering with MYC function. As part of these efforts, 
this thesis work centres around evaluating these two different strategies to inhibit MYC 
functions and develop new treatments for cancer therapy. 
 
In paper I and II, we focused on the ability of MYC to block oncogene-induced 
senescence, and if it is feasible to target this function as anti-cancer treatment. Since 
MYC-mediated senescence suppression was previously shown to rely on its 
phosphorylation by CDK2, we investigated whether targeting CDK2 could halt MYC-
driven tumor development in vivo. We demonstrated that inhibiting CDK2, either 
pharmacologically or genetically, indeed induced senescence in MYC-driven mouse 
AML and lung tumor mouse models, reduced tumor burden and increased survival. In 
addition to senescence induction, our data suggest that CDK2 depletion reverses MYC-
mediated immune suppression in lung tumors, resulting in infiltration and activation of 
adaptive and innate cells into the tumor area. The exact nature of different immune 
subpopulations involved and their activities in relation to MYC and CDK2 status are yet 
to be dissected, which will provide additional insight on MYC regulation of the immune 
response during tumorigenesis. We conclude that CDK2 inhibition is a promising strategy 
for future anti-MYC cancer therapies and warrant a need for the development of more 
specific and potent CDK2 inhibitors. Further, the role of CDK2 in MYC 
immunomodulatory functions has a promising potential to be exploited for possible 
combination treatment with immune therapy. 
 
In paper III and IV, we focused on identification and characterization of small molecule 
inhibitors that block the dimerization of MYC with its obligatory partner, MAX. Two 
compounds, MYCMI-6 and MYCMI-7, bound MYC directly in vitro and showed strong 
and selective inhibitory effect for MYC:MAX endogenous interaction in cells at low 
micromolar concentrations. Further, the two compounds efficiently inhibited MYC-
dependent tumor cell growth in cell cultures and in mouse tumor models in vivo with 




encouraging and warrant further investigation with respect to their mechanism of action 
and to the improvement of their efficacy and bioactivity for further pre-clinical/clinical 
development. In conclusion, these two approaches to interfere with MYC function 
showed promising results and can potentially pave the way for new advancements in anti-
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